

## Author Index to Volumes 30-36

- Abe M, 34:77  
 Abe R, 31:279  
 Abe T, 30:163; 30:183;  
     34:261  
 Abrams J, 36:1  
 Adhvaryu SG, 32:277  
 Agbor P, 30:301  
 Ai-Pu G, 32:217  
 Ajmar F, 31:105  
 Akao Y, 34:77  
 Åkerman M, 31:299;  
     34:209; 36:141;  
     36:173; 36:183  
 Aledo R, 33:29  
 Allen JE, 32:59  
 Allen SL, 33:111; 35:223  
 Ambros P, 34:265  
 Amorosi E, 35:223  
 Anastasi J, 35:143  
 Andrade JAD, 32:169;  
     32:177  
 Anthone R, 36:55  
 Anthone S, 36:55  
 Antony AC, 35:61  
 Aozasa K, 30:183  
 Arakawa S, 30:163  
 Archer SA, 35:179  
 Arheden K, 30:23;  
     30:323; 35:5  
 Arlin Z, 35:223  
 Atkin NB, 34:121  
 Attal M, 30:253  
 Audebert AA, 36:217  
 Aurias A, 32:229; 32:239;  
     33:29  
 Aventin A, 35:133  
 Ayraud N, 34:89  
  
 Babu VR, 32:301  
 Badia L, 31:165  
 Baer MR, 30:133; 35:199  
 Baker E, 31:25  
 Baker MC, 34:121  
  
 Balaban G, 30:313  
 Balar DB, 32:277  
 Bar J, 36:159  
 Baranger L, 34:11;  
     36:123; 36:225  
 Barbata G, 30:333; 32:143  
 Bartnitzke S, 35:129  
 Battersby RDE, 31:199  
 Bayle J, 34:89  
 Beard MEJ, 31:217  
 Becher R, 30:329; 34:265  
 Belasco JB, 36:211  
 Bellanca F, 32:143  
 Bellinger M, 31:285  
 Bello MJ, 32:295; 33:275;  
     35:55  
 Benn P, 35:51  
 Benn PA, 35:223  
 Bennett B, 36:89  
 Bennett JM, 34:1  
 Berger CS, 31:63; 31:69;  
     31:75  
 Berger MP, 32:229  
 Berger R, 32:67; 33:245;  
     34:11; 36:123; 36:225  
 Berheimm A, 36:123  
 Berk PD, 33:193  
 Bern MM, 30:83  
 Bernabei PA, 35:213  
 Bernheim A, 32:67;  
     33:245; 34:11  
 Bernstein R, 33:175;  
     36:45  
 Bertoglio MG, 30:151  
 Besa EC, 33:155; 35:141  
 Bessho M, 31:95  
 Bettelheim P, 34:265  
 Bianchi U, 34:251  
 Biegel JA, 30:91; 36:211  
 Bigner DD, 30:91  
 Bigner SH, 30:91  
 Bitter MA, 30:171  
 Bixenman H, 31:63  
  
 Björklund A, 30:177;  
     32:93; 32:305;  
     36:149; 36:233  
 Blatt J, 31:285  
 Bleehen NM, 30:213  
 Blin N, 33:127  
 Block AW, 36:55  
 Bodenizza C, 36:69  
 Boghosian L, 30:285;  
     30:339; 32:25;  
     32:263; 34:207;  
     36:131  
 Boldog F, 36:197  
 Boman BM, 34:153  
 Bong B, 30:319  
 Boogaerts M, 30:63;  
     31:147; 34:33; 36:165  
 Boros L, 36:31  
 Boswell HS, 35:61  
 Botti AC, 35:51  
 Boughton BJ, 34:29  
 Bourrouillou G, 30:253  
 Bown NP, 32:247; 36:25  
 Bowser-Riley SM, 31:271  
 Brecher ML, 34:277  
 Breed A, 30:319  
 Brian MJ, 30:187; 33:25  
 Briault S, 32:309  
 Bridge JA, 34:119  
 Brizard A, 32:309  
 Brookwell R, 32:297;  
     34:47  
 Brown J, 34:25  
 Brown JA, 34:165  
 Brown RS, 31:69  
 Brown S, 36:109  
 Brown T, 36:89  
 Brunet S, 35:133  
 Brunoni D, 32:169  
 Bryand E, 30:139  
 Bugat R, 30:253  
 Buist J, 32:51; 35:159;  
     35:171; 36:7

- Bullerdiel J, 35:129  
 Buys CHCM, 32:281;  
 33:127  
 Cacangiu ML, 35:83  
 Calabrese G, 34:251  
 Camuto PM, 31:301  
 Cannizzaro LA, 33:93;  
 35:142  
 Caporossi D, 36:13  
 Carbone P, 30:333;  
 32:143  
 Carbonell F, 30:329  
 Carda C, 33:311  
 Carlson RO, 32:59  
 Carotenuto M, 36:69  
 Carotti A, 32:205  
 Carr K, 31:35  
 Carritt B, 32:281  
 Casalone R, 34:257  
 Castedo SMMJ, 30:53;  
 32:51; 32:149;  
 34:219; 35:159;  
 35:171; 36:7  
 Catovsky D, 32:217  
 Cengiz K, 36:55  
 Cervantes F, 31:165  
 Chang KS, 30:103  
 Chen P, 31:157  
 Chen SJ, 34:11  
 Chen TR, 33:77  
 Chen Y, 32:101  
 Cherif D, 33:245  
 Chiu H, 35:279  
 Chopita N, 31:171  
 Chretien B, 33:29  
 Christian BJ, 36:77  
 Christiansen H, 34:235  
 Christoffersen P, 35:27  
 Chuang S, 32:101  
 Clark WH Jr, 30:313  
 Clouston WM, 30:127  
 Cochrane JM, 35:179  
 Colin F, 34:201  
 Colombies P, 30:253  
 Conway T, 36:205  
 Cooper I, 31:179  
 Cooper MR, 36:109  
 Cork AM, 32:287  
 Cornaglia-Ferraris P,  
 30:225; 32:293  
 Couturier D, 32:253  
 Couturier J, 33:67  
 Couturier-Turpin M,  
 32:253  
 Cowell JK, 34:223  
 Coyle T, 33:193  
 Coyle-Morris JF, 31:69  
 Cram LS, 35:119  
 Crawford P, 36:25  
 Crickard K, 32:263  
 Cuisenier J, 34:201  
 Cullen DF, 31:25  
 Cunningham JJP, 33:213  
 Daenen S, 30:319  
 Dal Cin P, 30:17; 30:133;  
 30:145; 30:201;  
 30:339; 30:285;  
 30:289; 31:35;  
 31:237; 31:263;  
 32:25; 32:263;  
 32:313; 34:111;  
 34:207; 35:41; 35:47;  
 36:1; 36:131  
 Dallapiccola B, 36:69  
 Dalton WT Jr, 32:287  
 Daly H, 31:193  
 Dam A, 30:53; 32:51;  
 34:219  
 Daniel A, 32:299  
 D'Arrigo P, 32:153  
 da Silva MAP, 32:109;  
 36:35  
 Dastugue N, 30:253  
 Davies SV, 31:271  
 Davis EM, 30:171  
 Davison EV, 31:193;  
 32:247; 36:25  
 Dawson AA, 36:89  
 de Braekeleer M, 35:279  
 de Campos JM, 33:275;  
 35:55  
 Decker HH, 33:59; 34:117  
 Decker HJ, 32:267  
 Deferrari R, 31:105  
 de Gramont A, 36:137;  
 36:217  
 de Jong B, 30:53; 30:319;  
 32:51; 32:149;  
 34:219; 35:159;  
 35:171; 36:7  
 Delannoy A, 36:203  
 Della Porta G, 30:151  
 DeLoup J, 36:137  
 Deminatti M, 33:99  
 Demur C, 30:253  
 Derre J, 34:11  
 Devlin JT, 35:273  
 Dewald GW, 32:59  
 Dickson BJ, 31:179  
 Ding JC, 34:25  
 Donaldson MH, 35:167  
 Donti E, 30:225; 32:205  
 Donti GV, 32:205  
 Dossu J, 35:273  
 Dreazen O, 32:217  
 Dreyfus B, 32:309  
 Drivsholm A, 35:27  
 Dürst M, 33:93  
 Dutrillaux B, 32:43;  
 33:29; 33:67  
 Dyer M, 31:247  
 Eiseman E, 34:165  
 Ejima Y, 30:119  
 Ekblom L, 32:299  
 Ekedahl C, 33:229  
 Ellsworth JL, 36:191  
 Emanuel BS, 32:13;  
 36:211  
 Enomoto Y, 34:5; 35:151  
 Erbe RW, 35:273  
 Erlandsson R, 36:197  
 Erwenne CM, 32:169;  
 32:177  
 Esnous C, 32:253  
 Estienne MH, 33:99  
 Fan Y, 30:133; 31:241;  
 31:263; 32:153  
 Feminic-Kes R, 35:37  
 Fenaux P, 33:99  
 Fernandez LA, 33:139  
 Ferrini PR, 35:213  
 Ferrucci L, 34:251  
 Ferti AD, 34:101  
 Ferti-Passantonopoulou  
 A, 35:41  
 Fiebig H, 33:305  
 Filomena CA, 35:237  
 Fischer P, 31:247  
 Fischer H, 33:127  
 Fiser J, 35:279  
 Fitzgerald PH, 31:217;  
 34:285; 35:179  
 Fitzsimmons ML, 36:205  
 Flandrin G, 36:123  
 Flejter WL, 32:201  
 Floderus U, 32:13; 36:183  
 Foroni L, 32:217  
 Franke F, 34:235  
 Franssila K, 34:305  
 Frassoni F, 31:105  
 Fratini A, 31:25  
 Frei E III, 30:83  
 Freireich EJ, 30:103  
 Fridrik M, 34:265  
 Friedman HS, 30:91  
 Fujieda H, 35:151  
 Fujishita M, 34:281  
 Fujita N, 36:103  
 Fuzibet JG, 34:89

- Gardner HA, 35:279  
 Gardner-Medwin D, 36:25  
 Gargano D, 31:275  
 Garson OM, 30:43; 31:179; 34:25  
 Gemmill RM, 31:69; 31:75  
 Genuardi M, 33:201  
 Ghione F, 31:275  
 Ghose T, 33:139  
 Ghosh PK, 32:211; 36:177  
 Ghosh R, 32:211; 36:177  
 Gibas, LM, 35:237  
 Gibas Z, 32:19; 35:237  
 Gibson SH, 35:273  
 Giglio MC, 30:333  
 Gil R, 33:311  
 Giles FJ, 34:273; 35:231  
 Giles LM, 34:283  
 Gilgenkrantz S, 30:337  
 Giovanella BC, 35:5  
 Giraud C, 32:309  
 Glover TW, 31:69  
 Goldman J, 32:217  
 Goldstone AH, 34:273  
 Gonzalez-Canali G, 36:137; 36:217  
 Gotoh H, 36:103  
 Govaerts L, 30:319  
 Graeven U, 34:265  
 Granata G, 30:333; 32:143  
 Grant G, 34:247  
 Greco MA, 31:301  
 Greco MM, 36:69  
 Greeley TA, 30:83  
 Green DM, 34:277  
 Greenbaum BH, 35:167  
 Greene MH, 30:159  
 Gregorio JS, 35:263  
 Griffin CA, 32:19; 32:129  
 Grigani F, 32:205  
 Grossi A, 35:213  
 Grossman A, 35:223  
 Groupe Francais de Cytogenetique, Hematologique, 32:157; 35:243  
 Growney P, 33:155; 35:141  
 Grubisic G, 35:269  
 Guanciali-Franchi P, 34:251  
 Guazzelli C, 31:275  
 Gucalp R, 34:19  
 Haaf T, 30:73  
 Haas OA, 34:265  
 Halbrecht I, 31:113  
 Hagemeyer A, 34:91  
 Hanada R, 30:343; 33:145; 34:41  
 Harbott J, 31:83  
 Harper P, 31:247  
 Harris BN, 30:171  
 Harth H, 33:185  
 Haruyama H, 36:103  
 Hasegawa S, 34:295  
 Hashimoto K, 34:53  
 Haubrich J, 35:129  
 Haupt R, 32:293  
 Hayashi Y, 30:343; 33:145; 34:41  
 Hayhoe FGJ, 30:261; 31:247; 34:29  
 Hayward NK, 30:127  
 Hecht BK, 31:47; 31:63; 31:75; 33:1; 33:93; 35:73; 35:79; 35:283  
 Hecht F, 30:181; 31:1; 31:17; 31:47; 31:63; 31:69; 31:75; 31:119; 31:125; 31:129; 31:132; 31:142; 31:295; 32:267; 33:1; 33:93; 33:151; 33:153; 34:155; 34:195; 35:73; 35:79; 35:283  
 Heerema N, 32:109  
 Heerema NA, 35:61  
 Heim S, 30:23; 30:177; 30:323; 31:299; 32:13; 32:93; 32:305; 33:11; 33:299; 34:209; 34:241; 35:5; 35:103; 36:141; 36:149; 36:173; 36:183; 36:233  
 Henderson AS, 30:269  
 Henn W, 33:127  
 Higashi O, 34:53  
 Higgins JV, 31:291  
 Hino O, 30:269  
 Hirai M, 30:295  
 Hirashima K, 31:95  
 Hittelman WN, 30:301  
 Hoene E, 31:211  
 Hoffman R, 32:109; 35:61; 35:205  
 Holden JJA, 32:117  
 Hollings PE, 31:217; 34:285  
 Hopper JL, 31:179  
 Horgas G, 35:269  
 Hori T, 31:95; 34:177; 34:189  
 Horn M, 31:285  
 Horsman DE, 36:155  
 Hossfeld DK, 30:165; 33:19; 35:205; 36:55  
 Hough MR, 32:117  
 Hoyle CF, 30:261; 31:247; 34:29  
 Huang J, 31:157  
 Huart JJ, 33:99  
 Huben R, 32:313; 35:41  
 Hunt FA, 32:297; 34:47  
 Huret JL, 32:309  
 Ibson JM, 30:213  
 Ichimaru M, 36:221; 36:227  
 Idenburg VJS, 30:53; 35:171  
 Ikeuchi T, 30:295  
 Imashuku S, 30:163  
 Inaba T, 30:343; 34:41  
 Ironside JW, 31:199  
 Ishi M, 30:341  
 Ishihara T, 31:95; 32:75; 33:161; 34:177; 35:263  
 Ito H, 31:31; 33:83; 33:119; 36:231  
 Ito M, 30:239  
 Itoh K, 36:103  
 Itoyama T, 36:221  
 Iurlo A, 36:143; 36:165  
 Iwabuchi H, 35:151  
 Jackson CE, 32:301  
 Jackson L, 34:57  
 Jackson LG, 35:237  
 Jaffe R, 31:285  
 Jalbert H, 36:159  
 Janardhana V, 31:179  
 Jani KH, 32:277  
 Jansen J, 36:35  
 Jiahui X, 35:135  
 Jianyun X, 35:135  
 Jin Y, 30:177; 32:93; 32:305; 33:11; 33:133; 36:149; 36:233  
 Johansson B, 33:51; 33:299  
 Jonsson N, 36:149  
 Juneja S, 34:25  
 Kakati S, 34:111  
 Kalousek DK, 36:155  
 Kamei T, 36:221  
 Kameyama J, 35:281




- Kaminer LS, 30:171  
 Kamst E, 34:91  
 Kaneko A, 30:119  
 Kaneko Y, 30:109; 34:177  
 Karakousis C, 30:145;  
 30:201  
 Kardon N, 33:111  
 Kariyone S, 31:279  
 Karlsson I, 34:241  
 Kaštelan M, 35:37  
 Kato K, 34:77  
 Katz SN, 35:83  
 Kawakami M, 30:295  
 Kawauchi S, 35:281  
 Kerim S, 34:33  
 Kernahan J, 31:193  
 Kessler LG, 35:109  
 Kidd P, 30:139  
 Kimberling WJ, 34:153  
 Kinniburgh AJ, 30:233;  
 30:239; 33:83; 34:111  
 Kinoshita K, 36:227  
 Kirschner J, 31:241  
 Klar D, 31:113  
 Klein G, 36:197  
 Knight C, 31:247  
 Knuutila S, 33:251;  
 34:305  
 Kohli M, 31:193  
 Koie K, 34:77  
 Koike K, 34:77  
 Kok K, 32:281  
 Komatsu K, 34:53  
 Kondo M, 36:231  
 König JJ, 34:91  
 Konja J, 35:37  
 Koops HS, 32:51; 32:149;  
 35:159; 36:7  
 Kouba M, 34:135  
 Kovacs G, 31:211; 33:305  
 Kramer PM, 35:119  
 Kristoffersson U, 31:299;  
 33:133; 35:103;  
 36:173  
 Krulik M, 36:137; 36:217  
 Kubonishi I, 34:281  
 Kühn D, 30:329  
 Kuhn EM, 34:143  
 Kulkarni R, 31:291  
 Kurosawa Y, 34:77  
 Kurzrock R, 34:57  
 Kusak E, 33:275  
 Kusak ME, 35:55  
 Kuse R, 33:19; 35:205  
  
 Labal de Vinuesa M,  
 31:171; 31:175  
 Lai JL, 33:99  
  
 Lampert F, 31:83; 34:235  
 Lanino E, 30:225  
 Larripa I, 31:171; 31:175  
 Larson RA, 35:143  
 Lauer RC, 35:61  
 Laug WE, 35:1  
 Le Beau MM, 30:171;  
 31:55; 35:143  
 Lecca U, 32:13; 32:33  
 Le Coniat M, 33:245;  
 34:11  
 Lee CLY, 33:139  
 Lee F, 32:101  
 Lee SHS, 33:139  
 Leeuw JA, 32:149  
 Leeuw JB, 36:7  
 Legon S, 32:217  
 Lenoir GM, 32:229  
 Leone G, 33:201  
 Leong SPL, 34:117;  
 36:131  
 Leroux D, 36:159  
 Li C, 31:157  
 Li FP, 31:69; 32:313;  
 34:111; 35:41; 36:1  
 Li Y, 35:143  
 Liang JC, 30:103  
 Lichtman S, 33:111  
 Liedgren S, 32:13  
 Limon J, 30:201; 34:111;  
 35:41  
 Lin D, 32:101  
 Lindholm C, 34:305  
 Lippi A, 31:275  
 Lisse IM, 35:27  
 Little BB, 35:109  
 Little MH, 30:127  
 Liu C, 32:101  
 Lizard S, 32:229; 32:239  
 Lizard-Nacol S, 34:201  
 Ljungberg B, 32:35  
 Llombart-Bosch A,  
 33:291; 33:311  
 Lloyd DA, 31:285  
 LoBue J, 35:91  
 Lockwood D, 31:63; 33:1  
 Lombard M, 33:67  
 Long PP, 32:129  
 Longo L, 30:225  
 Lopez-Gines C, 33:291;  
 33:311  
 Louvel A, 32:253  
 Louwagie A, 30:63;  
 31:147  
 Lowe LR, 36:35  
 Luck JB, 34:165  
 Lundgren R, 33:133;  
 35:103  
  
 Luyun L, 35:135  
 Luzzatto L, 32:217  
 Lynch HT, 34:153;  
 36:205  
 Lynch JF, 36:205  
  
 Macera MJ, 35:51  
 Mackinnon WB, 30:43  
 Maekawa T, 34:261  
 Majolino I, 32:143  
 Malcolm AJ, 32:247  
 Maltby EL, 31:199  
 Mamaev N, 35:21  
 Mamaeva S, 34:63; 35:21  
 Mancini R, 33:201  
 Mandahl N, 30:23;  
 30:177; 30:323;  
 31:299; 32:13; 32:93;  
 32:305; 33:11;  
 33:299; 34:209;  
 34:241; 35:5; 35:103;  
 36:141; 36:149;  
 36:173; 36:183;  
 36:233  
 Mandich P, 31:105  
 Mango G, 33:201  
 Maria BL, 34:247  
 Mark J, 30:91; 33:229  
 Martelli MF, 32:205  
 Maseki N, 30:109  
 Maserati E, 34:257  
 Matthews C, 33:25  
 Matsuo T, 34:1  
 Mattson K, 33:251  
 Mayakova AS, 32:183  
 Mazabraud A, 32:229  
 McCormack MK, 35:167  
 McMorrow LE, 35:167  
 McNay JW, 36:109  
 Mecucci C, 30:63;  
 31:147; 32:205;  
 34:33; 35:213;  
 36:143; 36:165;  
 36:203  
 Meier CB, 33:19  
 Meisner LF, 36:77  
 Meiss R, 31:171  
 Melaragno MI, 32:177  
 Melodia A, 30:225  
 Mendez MJ, 33:93  
 Mensink HJA, 30:53  
 Mertens F, 33:51;  
 33:299  
 Meyer K, 35:129  
 Mezzanotte R, 34:251  
 Michael PM, 30:43  
 Michalova K, 33:39

- Michalski K, 34:135  
 Michaux J, 31:147;  
     36:143; 36:165  
 Miles J, 34:135  
 Mills AS, 34:165  
 Miniamihihamatsu M,  
     31:95; 32:75; 33:161;  
     34:177; 35:263  
 Minowada J, 30:239;  
     33:83  
 Misawa S, 30:163;  
     34:261; 36:103  
 Mitelman F, 30:23;  
     30:177; 30:323;  
     31:299; 32:13; 32:93;  
     32:305; 33:11;  
     33:299; 34:209;  
     34:241; 35:5; 35:103;  
     36:141; 36:149;  
     36:173; 36:183;  
     36:233  
 Mitra J, 35:91  
 Miura AB, 34:53  
 Miura I, 34:53  
 Miwa S, 34:295  
 Miyahi T, 34:281  
 Miyoshi I, 34:281  
 Monteil M, 36:159  
 Moore NR, 36:89  
 Moran J, 34:119  
 Moreau L, 33:155; 35:141  
 Moreno S, 33:275  
 Morgan E, 30:171  
 Morgan R, 30:159; 31:47;  
     32:267; 35:79; 36:31  
 Morgan SS, 36:31  
 Mori H, 31:279  
 Mori M, 30:295  
 Morris CM, 35:179  
 Mortimer RH, 30:127  
 Muchi H, 33:145  
 Mudry de Pargament M,  
     31:171; 31:175  
 Mugneret F, 32:229;  
     32:239; 34:201  
 Muleris M, 32:43  
 Müller H, 33:149  
 Müller L, 33:305  
 Murakami S, 36:103  
 Murata M, 31:95; 34:189;  
     34:177  
 Murray JA, 31:271  
 Musilova J, 33:39  
  
 Nacheva E, 31:247  
 Nahashi Y, 34:5  
 Nahreini P, 35:61  
 Najfeld V, 33:193  
  
 Nakagawa M, 36:103  
 Nakajima F, 30:163  
 Nakamura H, 36:221;  
     36:227  
 Nakamura I, 36:221  
 Nakanishi S, 36:103  
 Nakashima M, 34:41  
 Nakić M, 35:37  
 Naoe T, 34:77  
 Neerema NA, 36:35  
 Neff JR, 34:119  
 Nepveux P, 32:253  
 Neri G, 33:201  
 Neumann HPH, 31:41;  
     33:59  
 Nicoletti B, 36:13  
 Nieddu M, 30:35  
 Niiya K, 34:281  
 Nilbert M, 32:13; 34:209;  
     36:141; 36:183  
 Nishido T, 34:41  
 Nishinari T, 34:53  
 Nishino K, 30:191  
 Nishio A, 36:103  
 Noguera R, 33:311  
 Noll WW, 35:273  
 Nomura K, 30:233  
 Nordenson I, 32:35  
 Norris MD, 30:187; 33:25  
 Nowell PC, 30:313;  
     33:155; 34:57; 35:141  
  
 Oaks MK, 31:291  
 Ohsumi A, 36:231  
 Ohtsuki Y, 34:281  
 Ohyashiki JH, 30:233;  
     30:239; 31:31; 33:83;  
     33:119; 34:5; 34:159;  
     35:151; 36:227  
 Ohyashiki K, 30:233;  
     30:239; 30:295;  
     31:31; 33:83; 33:119;  
     34:5; 34:159; 35:151;  
     36:231  
 Oku N, 36:103  
 Okumura T, 35:281  
 Olschwang S, 32:229  
 Olsson H, 31:299;  
     36:173  
 O'Malley DP, 31:291  
 Onozawa Y, 35:263  
 Oosterhuis JW, 30:53;  
     32:51; 32:149;  
     32:281; 34:219;  
     35:159; 35:171; 36:7  
 Orts A, 31:165  
 Ozkaynak MF, 35:1  
  
 Pacot A, 34:11  
 Paietta E, 34:19  
 Pakkala A, 34:305  
 Palka G, 34:251  
 Panani AD, 34:101  
 Panarello C, 31:105  
 Pantzar JT, 36:155  
 Papenhausen P, 34:19  
 Parmiter AH, 30:313  
 Pathak S, 34:247  
 Patterson D, 35:21  
 Pavelka K, 30:83  
 Pavlova VA, 35:21  
 Pearson ADJ, 32:247;  
     36:25  
 Pedersen-Bjergaard J,  
     31:227  
 Pees H, 33:185  
 Pellin A, 33:291; 33:311  
 Perla G, 36:69  
 Perle MA, 35:223  
 Perry R, 36:25  
 Persky M, 31:301  
 Pestalozzi BC, 33:149  
 Petkovic I, 30:301; 35:37  
 Pettenati MJ, 36:109  
 Phebus CK, 31:285  
 Philip I, 32:229  
 Philip P, 31:227  
 Philip PJM, 34:89  
 Philip T, 32:229  
 Phillips CN, 35:253  
 Phillips S, 32:299  
 Pierotti MA, 30:151  
 Pietrzak E, 34:111  
 Pilotti S, 30:151  
 Pinto M, 36:45  
 Poirier Y, 32:253  
 Pollet JP, 33:99  
 Potter AM, 33:213  
 Powell BL, 36:109  
 Preisler HD, 30:133;  
     32:133; 35:199  
 Prentice TC, 30:133  
 Priest JH, 35:253  
 Prieto F, 31:165  
 Prigogina EL, 32:183  
 Pris F, 30:253  
 Pritchard J, 34:223  
 Propert DN, 31:179  
 Prout GR, 32:313; 35:41  
 Przepiorka D, 30:139;  
     36:117  
 Przylepa KA, 31:145;  
     33:35  
 Puchkova GP, 32:183  
 Pujol-Moix N, 35:133  
 Puspurs AH, 31:25

- Rabbitts RH, 30:213  
 Rahemtulla A, 32:217  
 Rajić L, 35:37  
 Rao U, 30:17; 30:145  
 Raptis S, 34:101  
 Rassool F, 32:217  
 Raynaud SD, 34:89  
 Raza A, 31:187; 31:241;  
     32:153; 33:225  
 Redrow MW, 35:109  
 Rees JKH, 31:247  
 Rege-Cambrin G, 34:33  
 Reid MM, 31:193  
 Reiss R, 31:113  
 Rey JA, 32:295; 33:275;  
     35:55  
 Reznikoff CA, 36:77  
 Ribeiro MCM, 32:169;  
     32:177  
 Richards JDM, 35:231  
 Richie JP, 35:41  
 Richmond A, 35:253  
 Rilke F, 30:151  
 Ringressi A, 35:213  
 Ripley S, 30:269  
 Rodriguez E, 35:91  
 Rogler CE, 30:269  
 Romijn JC, 34:91  
 Roos G, 32:35  
 Rosendorff J, 33:175  
 Rosenthal DS, 30:83  
 Rosman I, 31:217;  
     34:285; 35:179  
 Rowe JM, 31:263; 32:153  
 Rowley JD, 30:171;  
     35:143  
 Rudolph B, 31:83; 34:235  
 Russell SJ, 34:273; 35:231  
 Ryan DH, 30:233  
 Rydholm A, 30:23;  
     30:323; 33:299;  
     34:209; 34:241;  
     36:141  
  
 Sadamori N, 36:221;  
     36:227  
 Sait SNJ, 30:133; 30:201;  
     31:187; 31:241;  
     32:153; 33:225;  
     34:277; 35:47  
 Sakai K, 30:119  
 Sakurai M, 30:109;  
     35:281  
 Salmon RJ, 32:43; 33:67  
 Sanada I, 30:341  
 Sandberg AA, 30:17;  
     30:133; 30:145;  
     30:159; 30:201;  
     30:233; 30:239;  
     30:289; 30:339; 31:1;  
     31:35; 31:63; 31:75;  
     31:187; 31:237;  
     31:241; 31:263;  
     32:11; 32:25; 32:153;  
     32:263; 32:267;  
     32:313; 33:1; 33:59;  
     33:83; 33:225;  
     34:111; 34:117;  
     34:207; 34:277;  
     35:41; 35:47; 35:199;  
     35:283; 36:1; 36:31;  
     36:55; 36:131  
 Sandbrink F, 33:305  
 Sandros J, 33:229  
 Sanger WG, 34:119  
 Sansone R, 32:293  
 Santoro A, 30:333  
 Sasagawa I, 36:221  
 Sasaki MS, 30:119  
 Sato T, 31:279  
 Savary JB, 33:99  
 Savelyeva L, 34:63  
 Scanlon DJ, 35:231  
 Scaravaglio P, 34:33  
 Scarpa RM, 30:35  
 Schachat AP, 32:129  
 Schaefer UW, 34:265  
 Scheffer H, 33:127  
 Schempp W, 31:41  
 Schimke RT, 36:191  
 Schmid M, 30:73  
 Schmidt CG, 30:329;  
     34:265  
 Schneider NR, 35:109  
 Schreiman J, 36:205  
 Schröder FH, 34:91  
 Schroeder WT, 30:103  
 Schüller H, 33:11  
 Schulman P, 33:111  
 Schumer J, 31:187  
 Schwartz PE, 35:83  
 Schwarzacher-Robinson  
     T, 35:119  
 Schwenk GR JR, 32:109  
 Second MIC Cooperative  
     Study Group, 30:1  
 Segenreich E, 35:91  
 Serra A, 33:201  
 Seruca R, 32:51; 32:149;  
     35:159; 35:171; 36:7  
 Seshadri R, 33:25  
 Sessarego M, 31:105;  
     32:293  
 Shabtai F, 31:113  
 Shaffer B, 34:119  
 Shamoto M, 34:77  
 Shapiro LR, 35:223  
 Sharma JK, 36:177  
 Sheer D, 30:277  
 Shen M, 32:101  
 Shende A, 30:245  
 Sheppard DM, 30:277  
 Sherrington P, 30:261;  
     31:247  
 Shigeno K, 36:227  
 Shiku H, 34:77  
 Shimazaki C, 36:103  
 Shinohara T, 34:295  
 Shipley JM, 30:277  
 Shipp MA, 30:83  
 Sidaner I, 32:229  
 Silver RT, 35:51; 35:223  
 Simmers RN, 31:9  
 Slavutsky I, 31:171;  
     31:175  
 Sleijfer DT, 32:51;  
     35:171  
 Smadja N, 36:137;  
     36:217  
 Smit B, 34:91  
 Smith MAC, 32:177  
 Smith PJ, 30:127  
 Solé F, 35:199  
 Solis V, 34:223  
 Sonoda Y, 34:261  
 Soudah B, 31:211  
 Sozzi G, 30:151  
 Spaventi S, 35:269  
 Spurbeck JL, 32:59  
 Sprandio J, 35:237  
 Sreekantaiah C, 33:225;  
     35:199  
 Srivastava A, 35:61  
 Stamberg J, 30:245  
 Stanley WS, 31:253  
 Stass SA, 30:103; 32:287  
 Steele MW, 31:285  
 Stehlin JS Jr., 35:5  
 Stein A, 31:187  
 Stein H, 34:305  
 Stenman G, 33:229  
 Sternberg A, 31:113  
 Stewart BW, 30:187  
 Strigini P, 32:293  
 Stuppia R, 34:251  
 Suarez HG, 33:245  
 Suciu S, 30:165; 33:19;  
     35:205  
 Sümegi J, 36:197  
 Sumner AT, 34:251  
 Susin M, 33:111  
 Sutherland GR, 31:5;  
     31:9; 31:25  
 Suzuki H, 31:279



- Tabilio A, 32:205  
 Tagawa M, 36:221  
 Taguchi H, 34:281  
 Tajara EH, 31:63; 31:75;  
     33:1  
 Takagi A, 30:295  
 Takagi M, 30:163  
 Takahashi E, 31:95;  
     34:177; 34:189  
 Takasaki N, 30:109  
 Takatsuki K, 30:341  
 Takeda N, 36:103  
 Takeda T, 30:295  
 Takeuchi T, 34:281  
 Takino T, 34:261  
 Talcott J, 36:1  
 Tammilehto L, 33:251  
 Taniwaki M, 30:183;  
     34:261  
 Tanooka H, 30:119  
 Tantravahi R, 30:83  
 Tanzer J, 32:309  
 Tedeschi B, 36:13  
 Teerenhovi L, 34:305  
 Terk-Zakarian J, 32:25  
 Therman E, 34:143  
 Thiery JP, 32:229  
 Third MIC Cooperative  
     Study Group, 32:1  
 Thomas J, 30:63  
 Thompson DS, 35:231  
 Tiainen M, 33:251  
 Tiefenbach A, 35:37  
 Tien H, 32:101  
 Tonini GP, 30:225  
 Tonomura A, 34:295  
 Toyama K, 30:239; 31:31;  
     33:83; 33:119; 34:5;  
     34:159; 35:151;  
     36:227; 36:231  
 Travis SF, 35:167  
 Tricot GJ, 35:61; 36:35  
 Trujillo JM, 30:103;  
     32:287  
 Tsuchiya K, 30:163  
 Tsuji E, 34:53  
 Tsujimoto M, 30:183  
 Tumminello P, 32:143  
 Turc-Carel C, 30:17;  
     30:145; 31:35;  
     31:237; 32:25;  
     32:229; 32:239;  
     34:201; 36:131  
 Twentyman PR, 30:213  
 Uchida A, 30:183  
 Uchida H, 36:231  
 Uchida T, 31:279  
 Ueda T, 30:183  
 Unteregger G, 33:127  
 Usai E, 30:35  
 Utsumi KR, 34:77  
 Valensi F, 36:123  
 van den Berg A, 32:281  
 Van Den Berghe H,  
     30:63; 31:147; 34:33;  
     35:213; 36:143;  
     36:165; 36:203  
 van der Hout AH, 32:281;  
     33:127  
 Van Dyke DL, 32:301  
 Van Orshoven A, 36:143;  
     36:165  
 Vanni R, 30:35; 32:13;  
     32:33; 34:251  
 Vardiman JW, 35:143  
 Vecchione D, 34:11  
 Verdone G, 30:225  
 Verma RS, 35:51; 35:223  
 Vernole P, 36:13  
 Viaplana J, 35:133  
 Vielh P, 33:67  
 Volk C, 32:229; 34:201  
 Volpe JPG, 34:125  
 Vowels MR, 30:187  
 Vyas RC, 32:277  
 Waintraub SE, 35:223  
 Walker H, 34:273; 35:231  
 Walter TA, 33:59; 34:117  
 Walter TW, 32:267  
 Wang C, 32:101  
 Wang T, 31:187; 31:241  
 Wang TY, 33:225  
 Wang Y, 35:253  
 Watanabe Y, 34:5; 35:151  
 Waters JJ, 30:213  
 Watmore AE, 33:213  
 Weaver DJ, 34:135  
 Webber LM, 30:43  
 Wedell B, 33:229  
 Weh H, 30:165; 33:19;  
     35:205  
 Weinstein ME, 35:223  
 Weiss A, 34:57  
 Wendt F, 30:329  
 Wenger SL, 31:145;  
     31:285; 33:35  
 Wennerberg J, 30:177;  
     32:93; 32:305;  
     36:149; 36:233  
 Westin EH, 34:165  
 White BN, 32:117  
 Wiedemann L, 32:217  
 Wienker TF, 31:41  
 Wiernik PH, 34:19  
 Wildrick DM, 34:153  
 Willem P, 36:45  
 Willén H, 30:23; 30:323;  
     34:209; 34:241;  
     36:141; 36:183  
 Wilmot PL, 35:223  
 Winfield DA, 33:213  
 Wolf M, 31:179  
 Wollenberg C, 33:127  
 Wolman SR, 31:301  
 Wong P, 31:95  
 Wu S, 36:77  
 Wurster-Hill DH, 35:273  
 Xiaoxuan H, 35:135  
 Yamada K, 34:77  
 Yamamoto K, 30:346;  
     33:145; 34:41; 34:295  
 Yang-Feng TL, 35:83  
 Yao E, 36:221  
 Yashige H, 36:103  
 Yatabe M, 34:53  
 Yim SO, 35:5  
 Ying K, 35:1  
 Yongshan Y, 31:253  
 Zaike Y, 30:295  
 Zang KD, 33:127  
 Zankl H, 33:185  
 Zaslav A, 30:245  
 Zelante L, 36:69  
 Zhang S, 31:157  
 Zollino M, 33:201  
 Zuazu I, 35:133





---

## Subject Index to Volumes 30-36

---

### Acute lymphoblastic leukemia (ALL)

- ALL (L2) with 11q23 changes, 31:279
  - ALL with unique 4;11, 31:291
  - B-cell with i(7q) and t(9;9), 30:295
  - bcr in 5', 32:217
  - childhood ALL, 32:183
  - chromosome changes and survival, 32:183
  - chromosomes in ALL, 32:183; 33:99
  - constitutional chromosome changes and, 35:243
  - Down syndrome and, 35:243
  - Ki-ras-2 in ALL cell line, 30:239
  - lineage infidelity in, 31:279
  - long survival in, 32:143
  - lymphomatous ALL, 33:149
  - NOR expression in, 35:109
  - PCC in, 35:37
  - Ph+ ALL, 32:183
  - pre-B-ALL cell line, 30:239
  - pre-B-cell ALL with t(1;19) and t(12;17); 31:275
  - radiotherapy-related, 31:227
  - t(1;18) in T-cell ALL, 30:165
  - t(8;14) and 1p- in L1 type ALL, 32:143
  - t(9;13)(p22;q12) in, 33:149
  - t(11;11) in ALL, 36:225
  - T-cell ALL with t(9;11), 31:263
  - +5 in ALL, 36:31
  - 7 and 12p- in secondary ALL, 31:227
  - 7, -16, +Ph, +mar, 32:64
  - 9p changes and, 33:99
  - 12p-, 32:64
  - 12p12 change in ALL cell line, 30:239
- ### Acute megakaryocytic leukemia (M7)
- after treatment of HD, 36:165
  - chromosome changes in, 33:111
  - congenital with t(1;22), 34:277
  - constitutional chromosome changes and, 35:243
  - Down syndrome and, 35:243
  - features of, 34:1
  - megakaryoblastic proliferation in MDS, 34:5
  - 5 in, 33:111

### Acute monoblastic leukemia (AMoL)

- after treatment of HD, 36:165
  - chromosome changes in, 34:11
  - constitutional chromosome changes and, 35:243
  - Down syndrome and, 35:243
  - in infant, 35:167
  - in transformed MPD, 32:157
  - inv(4) in M5b, 36:143
  - monoblastic cell line, 30:277
  - multiple chromosome changes in, 35:167
  - t(4;11) in infant, 35:167
  - t(8;16) in 34:265; 36:109
  - t(9;11) in, 30:171, 32:101
  - t(9;11;13) in, 30:171
  - t/del(11)(q13) in, 30:3
  - +8, +19, t(4;11) in, 35:167
  - 9p and 11q: critical regions, 30:171
  - +11 in M5a, 35:205
- ### Acute myeloblastic leukemia (AML)
- abnormal 16 in M2 with eosinophilia, 31:217
  - after treatment of HD, 36:165
  - chromosome changes, 30:3, 32:101; 34:11
  - constitutional chromosome changes and, 35:243
  - del(12)(p11-13) in, 30:3
  - Down syndrome and, 35:243
  - inv(4) in M1, 36:143
  - M2 following lung cancer in patient with constitutional extra chromosome, 35:263
  - M2 without t(6;9) and basophilia, 32:153
  - NOR expression in, 35:109
  - radiotherapy-related, 31:227
  - secondary with t(8;21)?, 31:271
  - t(1;3)(p36;q21) in, 33:194
  - t(1;16) in, 31:167
  - t(8;18;21) in M2, 36:231
  - t(8;21) variants, 33:163
  - t(8;21)(q22;q22) in, 30:3; 32:101; 33:161
  - t(9;22)(q34;q11) in, 30:3

## Acute myeloblastic leukemia—cont'd.

- t(12;19) with atypical erythropoiesis, 34:19
- tetraploidy after BMT, 36:69
- with variant t(8;21), 33:163
- 1q+ in cases with, 31:165
- +4 in M1 and M2, 34:29, 281
- +4 in M2, 34:281
- +11 in M1, 35:205

## Acute myeloid leukemia; see also Acute nonlymphocytic leukemia (ANLL)

- abnormal 16 in M2 with marrow eosinophilia, 31:217
  - after treatment of HD, 36:165
  - chromosome changes, 30:4; 31:167; 34:11
  - classification, 30:1-15
  - cytogenetics, 30:1-15; 31:167; 34:11
  - del(8)(q22) in RAEB-t transforming to M4, 30:319
  - FAB classification, 30:2
  - hypothesis on development, 32:133
  - immunoglobulin allotypes (Gm and Km), 31:179
  - karyotypic-morphologic associations, 30:3
  - protooncogenes in, 32:133
  - radiotherapy-related, 31:227
  - Second MIC Workshop, 30:1-15
  - secondary with t(8;21)?, 31:271
  - t(3;6) with abnormal thrombopoiesis and basophilia, 30:261
  - t(9;11) in, 30:171
  - t(12;19) with atypical erythropoiesis, 34:19
  - 5q- syndrome terminating in, 32:205
- Acute myelomonocytic leukemia (M4)
- after treatment of HD, 36:165
  - chromosome changes in, 32:101; 34:11
  - del(11)(q23) in, 30:3
  - dic(16;22) in M4, 35:143
  - distinct clones in, 35:213
  - in transformed MPD, 32:157
  - inv(16) and fragile site at 16q22, 31:31
  - inv/del(16)(q22) in, 30:3, 6; 31:31; 32:101
  - M4 following sarcoma of small intestine, 35:231
  - M4 with inv(16) and eosinophilia, 35:231
  - RAEB-t with del(8)(q22) transforming to, 30:319
  - t(1;3)(p36;q21) in, 33:194
  - t(1;16) in, 32:101
  - t(2;7) in M4 evolving from MDS, 35:199
  - t(6;9) without basophilia, 32:153
  - t(6;9)(p21-22;q34) with basophilia, 30:3
  - t(8;16)(p11;p13) in, 36:137

t(9;11) in, 30:171

t(9;11;18) in, 30:171

+4 in, 30:3; 33:19; 34:25; 36:155

6p+ and 9q- distinct clones in M4 evolving from MDS, 35:213

9p and 11q: critical regions, 30:171

+11 in M4, 35:205

## Acute nonlymphocytic leukemia (ANLL)

- after treatment of HD, 36:165
  - chromosome changes, 30:4; 34:11
  - chromosomes in 30 Chinese cases, 32:101
  - classification, 30:1
  - dic(16;22) in, 35:143
  - FAB classification, 30:2
  - hypothesis on development, 32:133
  - in transformed MPD, 32:157
  - isodicentric X, 30:43
  - inv(4) in ANLL, 36:143
  - protooncogenes in, 32:133
  - radiotherapy-related, 31:227
  - relapse and chromosome changes, 34:11
  - Second MIC Workshop, 30:1
  - t(1;3) in transformed PV, 33:193
  - t(1;3)(p36;q21) in, 33:194
  - t(2;7) in M4, 35:199
  - t(3;6) with basophilia and abnormal thrombopoiesis, 30:261
  - t(6;9) without basophilia, 32:153
  - t(9;11) in, 30:171
  - t(12;19) with atypical erythropoiesis, 34:19
  - t(16;21) with abnormal eosinophils, 36:221
  - triple X (XXX) constitution and, 35:1
  - +4 in ANLL, 36:155
  - 5q- syndrome terminating in, 32:205
  - 6p+ and 9q- distinct clones, 35:213
  - 7 in, 30:45
  - +11 in ANLL, 35:205
  - 11p15 in ANLL and MDS of childhood, 34:41
- Acute promyelocytic leukemia (APL)
- basophilia in APL with t(15;17) and t(9;14), 36:103
  - chromosome changes in, 34:11; 36:103
  - in Germany, 30:329
  - myeloperoxidase gene in, 30:103
  - r(6) and i(17q) in, 34:273
  - t(15;17) and t(9;14) in, 36:103
  - t(15;17)(q22;q12) in, 30:3, 103, 329; 32:101; 36:103
  - translocations from chromosome 17 to 15, 30:103
  - without t(15;17) but with other changes in, 34:273
- Adenoma
- colonic, chromosomes in, 32:11

- pleomorphic with t(3;8), 35:281
- Adipose tumors
  - chromosomes in lipoma, 32:11
  - lipoma with t(7;21), 30:17
  - 12q13-14 not involved with fragile site at 12q31.1, 31:35
  - 12q14 in translocations, 31:237
- Adrenal
  - adenoma and c-Ha-ras-1 locus, 30:127
  - in Wiedemann-Beckwith syndrome, 30:127
  - 11p and c-Ha-ras-1, 30:127
- Adult T-cell leukemia (ATL)
  - cell line ATN-1, 34:77
  - chromosome changes in pre-ATL, 30:191
  - chromosome instability, 30:191
  - cytogenetics of cell line, 34:77
  - pre-ATL states, 30:191
  - 14q11, 30:191
- Angiomyolipoma
  - +7 in, 34:219
- Agnogenic myeloid metaplasia
  - acute transformation, 32:157
  - chromosome changes in, 32:65
- AIDS
  - Burkitt lymphoma-leukemia, 32:67
  - cytogenetics of lymphoma in, 32:67
- Anemia
  - chromosome changes in RA, 31:148, 32:1
  - Fanconi and breakage, 33:175
  - idiopathic with sideroblasts (IASA), 30:45
  - refractory in childhood MDS, 34:41
  - t(1;7) in refractory anemia, 30:86, 88
  - Third MIC Workshop, 32:1
  - 6p rearrangements in refractory anemia, 31:148
- B-cell
  - ALL with i(7q) and t(9;9), 30:295
  - CLL with t(11;14) does not involve fragile site, 31:25
  - karyotypic stability in CLL, 33:155
  - pre-B-cell ALL with unique 4;11, 31:291
  - pre-B-cell ALL with (1;19) and (12;17), 31:275
- Basophilia
  - and chromosome changes, 30:3
  - in APL with t(15;17) and t(9;14), 36:103
  - t(3;6) and abnormal thrombopoiesis, 30:261
  - t(6;9) in M2 without, 32:153
- Benign tumors
  - chromosome changes in, 32:11
  - cytogenetic route of, 32:11
  - of salivary glands, 33:229
  - meningioma, 33:275
  - uterine leiomyoma with 12;14, 32:13, 19
  - 12 and 14 in uterine leiomyomas, 32:27
  - 12q in uterine leiomyoma, 32:33
  - 14q in uterine leiomyoma, 32:25
- Biotinylated probes
  - c-myc in colon adenocarcinoma, 33:245
  - chromosome localization, 33:245
- Bladder tumors
  - chromosomes #1, 3, 11 in, 30:35
  - cytogenetic changes in, 30:35
  - fragile sites, 31:63
  - +7 in, 30:35
  - 9 in, 30:35
- Blast crisis of CML
  - erythroblastic with 5q-, 34:261
- Bloom syndrome
  - cancer in, 30:181
  - DNA ligase I in, 30:181
- Bone marrow
  - cell cycle and growth, 31:157
  - changes after radiochemotherapy, 33:201
  - chromosome breaks in leukemia, 33:35
  - effects of cytostatic agents, 31:157
  - fragile sites in cells, 31:45, 145; 33:35
  - fragile sites in leukemic cells, 31:145; 33:35
  - methotrexate technique, 33:213
  - NOR expression in leukemia, 35:109
  - SCE in cells of, 31:157
  - thymidine release synchronization technique, 33:213
- Bone marrow transplantation (BMT)
  - cytogenetic patterns in, 36:35
  - in CML, 36:35
  - tetraploidy in AML (M1) after, 36:69
- Brain and CNS tumors
  - chromosome changes in, 30:91
  - double minutes in, 30:93
  - ependymoma, 30:289; 36:25
  - glioblastoma cell line, 33:127
  - medulloblastoma cell line, 34:247
  - meningiomas, 31:199; 32:11; 33:275
- Breakpoint cluster region (bcr)
  - bcr not rearranged in juvenile CML, 36:227
  - bcr zone break does not correlate with phase or prognosis of CML, 36:117
  - bcr+ Ph-negative CML, 35:223
  - breakpoint is 5' to bcr in AL, 32:217
  - in acute leukemia, 32:217
  - in ALL, 32:217
  - in MDS with Ph-like chromosome, 35:151
  - in Ph- CML, 33:119; 35:179
  - in variant Ph translocations, 35:179
- Breakpoints
  - chromosomal and cancer, 31:1-146



- Breakpoints—cont'd.  
 in hematological conditions, 31:132  
 in solid tumors, 31:129
- Breast cancer  
 family study in, 36:205  
 in obligate gene carrier, 36:205
- Burkitt lymphoma and leukemia  
 cell line, 34:63  
 chromosome changes in, 31:167; 32:67  
 heterogeneity, karyotypic of cell line, 34:63  
 in AIDS, 32:67  
 Raji cell line, 34:63  
 t(4;11) and Burkitt-like blasts, 34:89  
 t(8;14) in, 31:167; 32:67  
 t(8;22) in, 32:67  
 t(Y;1) in, 31:167
- C-band(s)  
 in non-Hodgkin's lymphoma cases, 31:175  
 polymorphism in lymphocytes of patients with colon adenomas and cancer, 31:171
- Cancer  
 chromosome breakpoints, 31:129, 132; 34:195  
 chromosome breakpoints and, 33:93  
 colorectal, 32:43  
 family syndrome and chromosome 18, 34:153  
 fragile sites and, 31:1–146; 34:177  
 genetic instability of, 34:125  
 integration of papillomavirus cancer breakpoints, 33:93  
 low chromosome counts and prognosis, 34:121  
 Robertsonian translocations in, 35:79  
 squamous cell carcinoma of tongue, 32:93
- Cell cycle  
 after cytostatic agents, 31:157  
 in marrow cells, 31:157
- Cell lines  
 adult T-cell leukemia, 34:77  
 Burkitt with karyotypic heterogeneity, 34:63  
 CLL cell line with 1q changes, 33:139  
 from small cell lung cancer (SCLC), 30:213  
 glioblastoma cell line with -13, -13, 33:127  
 hamster, 35:109  
 medulloblastoma, 34:247  
 melanoma, 35:5  
 melanoma with HSR, 32:117  
 meningiomas, 31:199; 33:275  
 monoblastic with chromosome changes, 30:277  
 neuroblastoma, 30:225  
 pre-B-ALL cell line, 30:239  
 prostatic adenocarcinoma, 34:91  
 tumorigenic diploid line, 33:77
- Centromere  
 antikinetochore antibodies and lack of centromeres in DMS, 30:73
- Chondrosarcoma  
 myxoid (extraskeletal) with t(9;22;15) in, 30:145
- Chromosome(s)  
 breakage in lymphocytes of patients with lymphoma, 33:51  
 breakage in lymphocytes of patients with musculoskeletal sarcoma, 33:299  
 breakpoints and cancer, 31:1  
 breaks in leukemia marrow, 33:35  
 damage induced by localized radiotherapy, 30:245  
 Xp11 in renal cancer, 30:53  
 1 in medulloblastoma, 30:91  
 1 in Merkel cell cancer, 30:152  
 1, 3, 11 in bladder tumors, 30:15  
 1, 6, 7 in melanoma, 30:201  
 1, 14, 10 and 19 in meningioma, 31:199  
 1p13 and 11p13 in leiomyosarcoma, 35:47  
 1q in endometrial cancer, 35:269  
 1q+ in hematologic and tumor states, 31:165  
 1q21 in renal cancer, 30:53; 34:233  
 3 and 5 in renal cancer, 35:41  
 3 in ANLL, 30:7  
 3p in renal cancer, 33:59  
 3p in SCLC cell lines, 30:213  
 3p, 17q, 6p, 19p in MDS, 32:1, 7  
 3p11-21 in renal cancer, 30:53, 32:35  
 3p14 in renal cancer, 31:75  
 5q- in secondary blood disorder, 30:253  
 6p in myelodysplasia, 31:148  
 6p+ and 9q- distinct clones in MDS and ANLL, 35:213  
 7, 22, and 1p11-22 in mesothelioma, 33:251  
 8 and 21 in ANLL, 33:161  
 8q12, 12q13-15, 3p21 in mixed salivary gland tumors, 33:229  
 9p and ALL, 33:99  
 9p and 11q in ANLL, 30:171  
 9q31 and 22q12.2 in chondrosarcoma, 30:145  
 10q24-26 in melanocytic neoplasia, 30:313  
 11 in CMMoL, 30:103  
 11 in myelodysplasia, 30:164  
 11p and 16 in Wilms' tumor, 34:223  
 11p in melanoma, 35:5  
 11p15 in childhood MDS, 34:41



- 11q in ANLL, 30:6
- 11q23 in ALL (L2), 31:279
- 11q23 in CMMoL, 30:341
- 11q23 in monoblastic leukemia line, 30:277
- 12p in ANLL, 30:9
- 12p12 in ALL cell line, 30:239
- 12q in lipoma, 36:131
- 14, 1p, and 11p in - 22 meningioma, 33:275
- 14q22 in renal cancer, 30:53
- 16 in AML (M2) with eosinophilia, 31:217
- 16 in ANLL, 30:6, 32:101
- 17 and 18 in colorectal cancer, 32:43
- 18q and #17 and integration site of hepatitis B DNA, 30:269
- 20q13 in medulloblastoma, 30:91
- Chromosome changes
  - after treatment of HD, 36:165
  - in acute megakaryoblastic leukemia, 33:111
  - in acute myeloid leukemia, 30:1, 4
  - in acute transformation of MPD, 32:157
  - in adult T-cell leukemia line, 34:77
  - in ALL, 33:99
  - in AMoL, 35:167
  - in ANLL, 30:1, 4, 171; 32:101; 34:11; 36:165
  - in ANLL in China, 32:101
  - in ANLL with t(8;21), 33:161
  - in APL, 30:329; 36:103
  - in APL, MPO t(15;17), 30:103
  - in benign tumors, 32:11
  - in bladder tumors, 30:35
  - in Burkitt cell line, 34:63
  - in childhood MDS, 34:41
  - in chondrosarcoma, 30:145
  - in CLL, 33:155; 34:295
  - in CMMoL, 30:109; 34:33
  - in colorectal tumors, 32:43; 34:101
  - in desmoid tumor (extraabdominal), 34:241
  - in dysplastic nevus syndrome, 35:73
  - in endometrial cancer, 33:67
  - in ependymoma, 30:289; 36:25
  - in fibrosarcoma, 30:323
  - in histiocytomas, 30:23
  - in large bowel cancer, 32:43; 34:101
  - in laryngeal cancer, 30:177
  - in leiomyosarcoma, 30:285, 339; 34:209; 35:47
  - in medulloblastoma, 30:91
  - in medulloblastoma cell line, 34:247
  - in melanoma, 30:201
  - in meningiomas, 31:199; 33:275
  - in Merkel cell carcinoma, 30:152
  - in mesothelioma, 33:251
  - in monoblastic cell line, 30:277
  - in MPD, 32:157
  - in myelodysplasia (MDS), 30:83, 163; 32:1, 157; 33:39; 34:33, 41; 35:21
  - in myelofibrosis, 30:139
  - in myeloma, 35:27
  - in Ph-negative CML, 31:241, 35:223
  - in plasma cell leukemia, 35:27
  - in prostatic cancer line, 34:91
  - in rectosigmoidal cancer, 34:101
  - in renal tumors, 30:53; 34:135; 35:41
  - in rhabdomyosarcoma, 30:343
  - in squamous cell carcinoma of tongue, 32:93
  - in synovial sarcoma, 30:183
  - in T-cell lymphoma, 36:123
  - in T-cell malignancies, 30:65
  - in uremia (including SCE), 36:55
  - in Wilms' tumor, 34:223
  - low chromosome counts and prognosis
    - in cancer, 34:121
  - of salivary gland tumors, 33:229
  - 1q+ in hematologic disorders, 31:165
  - 1q+ in tumors, 31:165
- Chronic lymphocytic leukemia (CLL)
  - cell line with 1q change, 33:139
  - chromosome changes in, 30:65; 33:155
  - cytogenetic study of CLL (T and B), 34:295
  - i(17q) in, 33:156
  - immunoglobulin allotypes Gm and Km, 31:179
  - karyotypic stability, 33:155
  - ring (1) in 33:155
  - t(10;19) and t(11;14) in B-CLL, 34:295
  - t(11;14) does not involve fragile site, 31:25
  - t(11;14) in, 33:156
  - T and B cell CLL, 34:295
  - with t(2;22;3), 32:65
  - + 12 in, 33:156
- Chronic myelocytic leukemia (CML)
  - bcr in Ph - CML, 33:119
  - bcr studies in Ph + CML, 35:179
  - bcr zone does not correlate with phase or prognosis, 36:117
  - bcr+ Ph-negative CML, 35:223
  - childhood MDS and CML, 34:41
  - chromosome patterns after transplantation, 36:35
  - complex chromosome changes in Ph-negative CML, 31:241
  - demethylation of DNA, 34:251
  - erythroblastic crisis with 5q -, 34:261
  - immunoglobulin allotypes Gm and Km, 31:179
  - juvenile without bcr rearrangement, 36:227
  - "masked" Ph, 30:333; 34:53

- Chronic myelocytic leukemia—*cont'd.*  
 molecular (restriction endonucleases), 34:251  
 molecular studies in Ph- CML, 33:119  
 NOR expression, 35:109  
 Ph-negative, 33:119  
 Ph-negative CML, 31:241; 33:119; 35:51, 223  
 Ph-negative juvenile, 36:227  
 Ph-negative with t(8;9), 35:51  
 radiotherapy-related (Ph+), 31:227  
 t(1;17) in CML, 34:257  
 t(3;9;22) in, 35:279  
 t(3;21) in, 35:133  
 t(4;18;13;9;22) in, 30:163  
 t(7;21)(p14;q11) in, 33:225  
 t(8;9) in Ph-negative CML, 35:51  
 t(9;11;22), masked Ph, 34:53  
 t(11;21) in Ph+ CML, 31:187  
 t(X;22) in, 30:333  
 variant Ph and fragile sites, 31:105  
 variant Ph translocations, 35:179  
 variant Ph translocations in, 32:75; 35:179  
 with 5 Phs, 34:257  
 27-year follow-up, 34:57
- Chronic myelomonocytic leukemia (CMML)  
 c-K-ras-2 overexpression in t(5;12) cases, 35:61  
 chromosome changes in, 31:148; 33:39; 34:285  
 in acute transformation of MPD, 32:157  
 t(5;12) in, 35:61  
 t(5;21) and del(7) in, 31:247  
 t(11;21) in, 34:33  
 t(Y;1)(q12;q21) in, 34:285  
 Third Workshop (MIC), 32:1  
 trisomy 11 (+11) in, 30:109  
 6p rearrangement in, 31:148  
 11p15 and childhood MDS and, 34:41  
 11q23 in, 30:341
- Classification  
 FAB, of ANLL, 30:2  
 of acute myeloid leukemia, 30:1  
 of ANLL, 30:1; 32:101  
 of MDS, 32:2
- Clone(s)  
 different clones (+5 and der (14)) in lymphoma, 36:173  
 distinct in MDS, 35:213  
 6p+ and 9q- in separate clones in ANLL, 35:213
- Colon cancer; see Large bowel cancer
- Congenital  
 Hu-ets-1 in, 30:233  
 leukemia with t(1;22), 34:277  
 leukemia with t(11;19), 30:233  
 rhabdomyosarcoma, 30:343
- Constitutional  
 chromosome changes, 35:243  
 chromosome changes in leukemic cells of cases with constitutional anomalies, 35:243  
 extra chromosome in patient with lung cancer and ANLL, 35:263
- Culture  
 tissue technique for mixed salivary gland tumors, 33:229
- Cytogenetic changes  
 in acute transformation of MPD, 32:157  
 in ALL, 33:99  
 in ANLL, 34:11  
 in ANLL in China, 32:101  
 in benign tumors, 32:11  
 in childhood MDS, 34:41  
 in CLL, 33:155; 34:295  
 in colorectal tumors, 32:43  
 in endometrial cancer, 33:67  
 in meningiomas, 31:199; 33:275  
 in mesothelioma, 33:251  
 in myelodysplastic disorders, 32:1, 157; 33:39; 34:33, 41; 35:21  
 in Ph-negative CML, 31:241; 35:223  
 in squamous cell carcinoma of tongue, 32:93  
 in tumors of salivary glands, 33:229  
 1q+ in hematologic disorders, 31:165  
 1q+ in tumors, 31:165
- Cytogenetics  
 after treatment of HD, 36:165  
 in ependymoma, 30:289; 36:25  
 in laryngeal cancer, 30:177  
 in rhabdomyosarcoma, 30:343  
 in synovial sarcoma, 30:183  
 of adult T-cell leukemia, 34:77  
 of AMoL, 35:167  
 of ANLL, 30:1, 4, 171; 32:101, 153; 33:163; 34:11; 36:165  
 of APL, 30:329; 36:103  
 of APL, MPO t(15;17), 30:103  
 of bladder tumors, 30:35  
 of Burkitt cell line, 34:63  
 of chondrosarcoma, 30:145  
 of CMML, 30:109; 34:33  
 of dysplastic nevus syndrome, 35:72  
 of fibrosarcoma, 30:323  
 of histiocytomas, 30:23  
 of large bowel cancer, 32:43; 34:101  
 of leiomyosarcoma, 30:285, 339; 34:209; 35:47  
 of medulloblastoma, 30:91  
 of melanoma, 30:201  
 of meningioma, 33:275  
 of Merkel cell carcinoma, 30:152  
 of mesothelioma, 33:251

- of monoblastic cell line, 30:277
  - of myelodysplasia, 30:83, 163; 34:33, 41
  - of myelofibrosis, 30:139
  - of myeloma, 35:27
  - of plasma cell leukemia, 35:27
  - of prostatic cancer cell line, 34:91
  - of rectosigmoidal cancer, 34:101
  - of renal adenocarcinoma, 30:53; 32:35; 34:135; 35:41
  - of T-cell lymphoma, 36:123
  - of T-cell malignancies, 30:65
  - of Wilms' tumor, 34:223
- Deletions**
- del(7q) and del(10q) in prostate cancer, 35:103
  - del(11)(q23) in M5 and M4, 30:3
  - del(12)(p11-13) in M2, 30:3
  - in bladder tumors, 30:37
  - in endometrial cancer, 33:67
  - in mesothelioma, 33:251
  - in myelodysplasia, 33:39
  - in renal cancer, 35:41
  - in T-cell malignancies, 30:65
  - in testicular tumor, 32:51
  - 1p in neuroblastoma, 34:235
  - 1p- in leiomyosarcoma, 30:285
  - 1p- in L1 type ALL, 32:143
  - 1q22 in myelodysplasia, 30:83
  - 3p- in prostatic leiomyosarcoma, 30:339
  - 3p- in renal cancer, 31:75; 32:35
  - 5q-, 7q-, 11q-, 12p-, 13q-, 20q- in MDS (primary), 32:6
  - 5q-, 7q-, 12p-, 3p-, 17q-, 19p- in treatment-related MDS, 32:7
  - 5q- in ANLL, 30:4; 31:227; 32:101, 205
  - 5q- in myelodysplasia, 30:136; 31:148; 32:157; 33:39
  - 5q- in Ph+ CML, 34:261
  - 5q- in secondary blood disorder, 30:253; 31:227; 32:157
  - 6q- and c-myb, 33:83
  - 6q- in melanoma, 30:201
  - 7q in uterine myoma, 34:207
  - 7q- in ANLL, 30:4; 32:101
  - 7q- in CMMoL, 31:247
  - 7q- in Merkel cell carcinoma, 33:305
  - 7q- in myelofibrosis, 30:139
  - 8p- in salivary gland tumor, 31:301
  - 8q- in Ph-negative CML, 31:241
  - 8q- in RAEB-t, 30:319
  - 9q- in ANLL, 30:4; 32:104; 33:163
  - 11p in leiomyosarcoma, 35:47
  - 12p- in radiotherapy-related ALL, 31:227
  - 12q- in colonic adenoma, 32:11
  - 13q- in CLL, 33:156
  - 13q- mosaicism in retinoblastoma, 32:177
  - 14q in uterine leiomyoma, 32:25
  - 14q- in uterine leiomyoma, 32:19
  - 17p- in colorectal cancer, 32:43
  - 20q- in ANLL, 30:4
  - 22q- in meningioma, 32:11; 33:275
- Desmoid tumor**
- chromosome changes in, 34:241
  - extraabdominal, 34:241
- Dicentric chromosomes**
- dic(16;22) in ANLL and MDS, 35:143
  - in bladder tumors, 30:37
  - in histiocytoma, 30:23
  - in meningioma, 33:275; 35:55
  - in mesothelioma, 33:251
  - origin in meningiomas, 35:55
- Distamycin A**
- and cancer, 34:177
  - inducible fragile sites, 34:177, 189
- DNA**
- content of testicular tumors, 32:51
  - flow cytometry in testicular tumor, 36:7
  - in cells fixed with Carnoy's solution, 34:159
  - studies in glioblastoma cell line with -13, -13, 33:127
- Double minute chromosomes (DMS)**
- antikinetochore antibodies and DMS, 30:73
  - breakdown of HSR into DMS in MDS, 34:47
  - in a case of AML (M2) with abnormal 16, 31:217
  - in a case of M4, 34:25
  - in medulloblastoma, 30:93
  - in meningioma, 33:275
  - in mesothelioma, 33:251
  - in myelodysplasia (RAEB), 34:47
  - in neuroblastoma cell lines, 30:225
  - in SCLC cell lines, 30:213
  - lack of centromere, 30:73
- Down syndrome**
- chromosomes in leukemic cells of, 35:243
  - leukemia in, 35:243
  - transient leukemoid reaction in, 35:243
- Dysplastic nevus syndrome (DNS)**
- chromosome changes in, 35:72
  - rearrangements in, 35:75
- Endometrial cancer and tumors**
- chromosome changes in, 33:67; 35:269
  - chromosome imbalance in, 33:67
  - stromal sarcoma, 36:1
  - trisomy and tetrasomy 1q in, 35:269
  - 1q in, 33:67



- Eosinophilia  
 and chromosome changes, 30:3  
 in marrow of M2 with abnormal 16,  
 31:217  
 in 8;21 translocation, 32:101  
 t(7;12) in a hypereosinophilic syndrome,  
 32:109
- Ependymoma  
 childhood, 36:25  
 chromosome changes in, 36:25  
 of ovary with +3, 35:83  
 supratentorial, 30:289  
 t(10;11;15) in, 30:289  
 -X in, 30:289
- Erythroleukemia  
 after treatment of HD, 36:165  
 chromosome changes in, 32:64; 34:11  
 constitutional chromosome changes and,  
 35:243  
 Down syndrome and, 35:243  
 t(1;3)(p36;q21) in, 33:194
- Erythropoiesis  
 t(12;19), ANLL and, 34:19
- Ewing's sarcoma  
 chromosome changes in, 31:167; 32:229  
 nonrandom chromosome changes,  
 32:239  
 t(1;16) in, 31:167  
 t(11;22) in, 31:167; 32:229  
 variant translocations, 32:229  
 +8 and t(1;16) in, 32:239
- FAB Classification  
 of ANLL, 30:2, 32:101  
 of myelodysplasia, 30:83, 32:2
- Family  
 breast cancer in, 36:205  
 cancer syndrome, 34:153  
 gene on chromosome 18, 34:153
- Fanconi anemia  
 chromosome breakage, 33:175  
 diepoxybutane (DEB) and mitomycin C  
 (MMC) and chromosome breakage,  
 33:175  
 studies in homo- and heterozygotes,  
 33:175
- Fibrosarcoma  
 with t(X;18), 30:323
- Fragile sites  
 at 11q13.3 not involved in CLL with  
 t(11;14), 31:25  
 cancer and, 31:1-146; 34:177, 195  
 cancer breakpoints, 31:1, 5, 9, 17, 25,  
 31, 35, 41, 47, 119  
 cancer breakpoints and oncogene  
 clustering, 31:17  
 cancer proneness, 34:177  
 distamycin A-inducible, 34:177  
 fra(8)(q24), fra(11)(p15), fra(16)(p12.1),  
 fra(16)(q22) and fra(17)(p12) -  
 distamycin A-inducible, 34:177  
 fragile site 1p13.1 and neuroblastoma,  
 31:83  
 fragile site 1q44 and nasopharyngeal  
 cancer, 35:135  
 fragile sites in MEN-2A, 35:273  
 in leukemic cells of marrow, 31:145;  
 33:35  
 in leukemic marrow, 33:35  
 in lymphocytes of neuroblastoma cases,  
 36:13  
 in patients with leukemia, 31:95  
 in patients with neuroblastoma, 36:13  
 in patients with urological tumors, 31:63  
 in renal cancer with t(3;8), 31:69, 75  
 in von Hippel-Lindau syndrome, 31:41  
 inv(16) in M4 and fragile site, 31:31  
 nature of distamycin A-inducible, 34:189  
 new common, 33:1  
 papillomavirus integration and, 33:93  
 rare and polymorphic in cancer, 34:195  
 unique to bone marrow, 31:47  
 update of, 31:125  
 variant Ph, 31:105  
 views on fragile sites and cancer, 31:1,  
 5, 55, 119; 34:177, 195  
 t(11;14) in B-cell leukemia does not  
 involve fragile site, 31:25  
 8q22 fragile site in large bowel tumors,  
 31:113
- Gammopathies; see also Myeloma and  
 Plasma cell leukemia  
 chromosomes in, 35:27  
 survival and chromosomes, 35:27
- Gene(s)  
 bcr in acute leukemias, 32:217  
 c-Ha-ras-1 homozygosity in adrenal  
 adenoma, 30:127  
 chromosome 18 and familial cancer,  
 34:153  
 for familial cancer, 34:153  
 genes involved in cancer stability,  
 34:128  
 Hu-ets-1 in congenital leukemia with  
 11;19, 30:233  
 Ig gene in acute leukemia, 32:217  
 Ki-ras-2 in ALL cell line, 30:239  
 myc amplification in SCLC cell lines,  
 30:213  
 myeloperoxidase in APL, 30:103  
 N-myc in retinoblastoma, 30:119  
 T-cell receptor, 32:217
- Genitourinary tumors  
 fragile sites in lymphocytes of patients  
 with, 31:63; 33:1



- t(3;8) in renal cancer and fragile site at 3p14, 31:69
- Glioblastoma  
cell line with -13, -13, 33:127  
molecular studies in cell line, 33:127
- Hamster (Chinese)  
NOR in cells, 35:109  
spontaneous in vitro neoplastic evolution, 35:109
- Hematologic malignancies  
t(8;21), -Y in granulocytic hyperplasia, 31:193  
Third MIC Workshop, 32:1  
1q+ in, 31:165
- Hepatitis B  
integration of DNA and chromosome aberration, 30:269  
18q and #17 and integration site, 30:269
- Heterochromatin; see C-banding  
in mouse and human nuclei, 34:143
- Histiocytoma  
chromosome changes in, 30:23  
in Reed-Sternberg cells, 34:305  
karyotype in, 34:305  
rings, dicentrics and telomeric association, 30:23
- Hodgkin's disease (HD)  
acute leukemias after therapy of HD, 36:165  
immunoglobulin allotypes Gm and Km, 31:179  
prognosis and chromosome changes, 31:299
- Homogeneously staining regions (HSR)  
breakdown into DMS, 34:47  
in mesothelioma, 33:251  
in SCLC cell lines, 30:207
- Homozygosity  
c-Ha-ras-1 in adrenal adenoma, 30:127
- Hypereosinophilic syndrome  
clonal nature, 32:109  
t(7;12) in, 32:109
- Hypodiploidy  
in meningioma, 33:275  
in mesothelioma, 33:251  
in renal cancer with 34 chromosomes, 31:211
- Hypopharynx  
inv(4) in cancer of, 36:233  
squamous cell carcinoma in, 36:233
- Idiopathic acquired sideroblastic anemia (IASA); see also Myelodysplasia  
chromosome changes in, 32:1  
isodicentric in, 30:45  
t(1;7) in, 30:83  
Third MIC Workshop, 32:1
- Immunoblastic sarcoma  
chromosome changes in, 30:65
- Immunology  
ALL immunophenotype, 30:12  
AML immunophenotype, 30:12  
immunofluorescence, centromere and double minutes, 30:73  
immunoglobulin allotypes Gm and Km in hematologic disorders, 31:179  
of acute myeloid leukemia, 30:11  
of ANLL, 30:11  
of MDS, 32:1  
Third Workshop (MIC) on MDS and, 32:1
- In situ hybridization  
myeloperoxidase gene in t(15;17), 30:103  
18q and #17 and integration site of hepatitis B DNA, 30:269
- Insertion  
ins(10;19) in endometrial sarcoma, 36:1  
ins(14;6)(q23;p23p25) in uterine leiomyoma, 34:201
- Inversions  
in meningioma, 33:275  
in mesothelioma, 33:251  
inv(2)(p22q24) in laryngeal cancer, 30:177  
inv(3)(q21q26) in M1 (M2, M4, M7), 30:3  
inv(4) in ANLL, 36:143  
inv(4) in squamous cell cancer of hypopharynx, 36:233  
inv(5) in MDS, 31:148  
inv(11)(p15q23) in childhood MDS, 34:41  
inv(12) in MDS, 31:148  
inv(16) in M4, 30:3; 31:31; 32:101  
inv(16) in M4 and fragile site at 16q22, 31:31  
inv(16) with eosinophilia, 35:231  
inv(18)(p11.3q21.1) in myelodysplasia, 30:137
- Isochromosomes  
double i(9p) in secondary MDS, 36:217  
in mesothelioma, 33:251  
i(7p) in Merkel cell cancer, 30:152  
i(7q) in B-cell ALL, 30:295  
i(7q) in CLL, 30:65  
i(8q) or i(9q) in lung cancer, 33:11  
i(12p) in testicular tumor, 32:51; 35:159  
i(17p) in ANLL, 30:4  
i(17q) in APL without t(15;17), 34:273  
i(17q) in CLL, 33:156  
i(17q) in medulloblastoma, 30:91  
i(17q) in plasma cell leukemia, 35:27  
i(17q) in Sézary syndrome, 30:65  
isodicentric X in MDS and ANLL, 30:43

- Juvenile CML  
 no bcr rearrangement in, 36:227  
 Ph-negative, 36:227
- Karyotypes and karyotypic changes  
 after treatment of HD, 36:165  
 in acute transformation of MPD, 32:157  
 in ALL, 33:99; 36:165  
 in ANLL, 33:163; 34:11  
 in APL, 30:329; 36:103  
 in B-cell ALL, 30:295  
 in benign tumors, 32:11  
 in childhood MDS, 34:41  
 in chondrosarcoma, 30:145  
 in CLL, 33:155; 34:295  
 in endometrial cancer, 33:67  
 in ependymoma, 30:289; 36:25  
 in fibrosarcoma, 30:323  
 in leiomyosarcoma, 30:285, 339; 34:209; 35:47  
 in melanoma, 30:201  
 in meningiomas, 31:199; 33:275  
 in Merkel cell cancer, 30:152  
 in mesothelioma, 33:251  
 in monoblastic cell line, 30:277  
 in myelodysplasia (MDS), 30:83; 31:148; 32:1, 33:39; 34:33, 41; 35:21  
 in myelofibrosis, 30:139  
 in Ph-negative CML, 31:241; 35:223  
 in radiotherapy-related leukemias, 31:227  
 in rhabdomyosarcoma, 30:343  
 in salivary gland tumors, 33:229  
 of Burkitt lymphoma cell line, 34:63  
 of dysplastic nevus syndrome, 35:73  
 of large bowel cancer, 32:43; 34:101  
 of myeloma, 35:27  
 of plasma cell leukemia, 35:27  
 of prostatic cancer line, 34:91  
 of rectosigmoidal cancer, 34:101  
 of renal tumors, 34:135; 35:41  
 of T-cell lymphoma, 36:123  
 of Wilms' tumor, 34:223
- Kidney tumors; see Renal tumors  
 Kinetochore; see Centromere
- Large bowel tumors  
 adenoma, chromosomes in, 32:11  
 C-band polymorphism in cases with, 31:171  
 c-myc in colon adenocarcinoma, 33:245  
 chromosome changes in colorectal tumors, 32:43  
 chromosome changes in rectosigmoidal cancer, 34:101  
 colorectal tumors, chromosomes, 32:43; 34:101  
 fragile sites in sisters with, 31:113  
 molecular cytogenetics, 31:295  
 near-diploid tumors (colorectal) 32:43  
 two processes in chromosome evolution, 32:43  
 8q- in colon cancer, 31:113  
 8q22 and 16q22 fragile sites in, 31:113  
 17p and -18 in colorectal tumors, 32:43
- Laryngeal tumors  
 chromosome changes in, 30:177  
 squamous cell cancer, 30:177
- Leiomyoma  
 del(7q) in uterine myoma, 34:207  
 r(1) in, 36:183  
 t(12;14) in, 36:183  
 uterine, chromosomes in, 32:11, 13; 34:201; 36:183  
 uterine, clonal rearrangements, 32:19; 34:201  
 #1 changes in, 36:183  
 3, 12, 14, 17 and 22 in uterine, 32:19  
 12 and 14 in uterine, 32:27; 36:183  
 12q in uterine, 32:33; 36:183  
 14q in uterine, 32:25; 34:201; 36:183  
 14q23 in uterine, 34:201
- Leiomyosarcoma  
 chromosome changes in, 30:285; 34:209  
 monosomy 9, 18 and 22 in, 35:47  
 of extremities, 34:209  
 of prostate, 30:339  
 of retroperitoneum, 35:47  
 of small bowel, 30:285  
 1p13 and 11p13 in, 35:47
- Leukemia(s)  
 acute mixed lineage, 33:185  
 acute with complex changes, 32:65  
 acute with t(9;11), 32:65  
 adult T-cell leukemia, 30:191  
 bilineage in, 30:12  
 biphenotypic, 30:12; 33:185  
 chromosome breaks in marrow, 33:35  
 congenital with t(11;19), 30:233  
 fragile sites in patients, 31:95  
 in acute transformation of MPD, 32:157  
 oligoblastic granulocytic with t(X;19), 35:237  
 XYY and leukemia, 30:337
- Lipoma  
 angiomyolipoma with +7, 34:219  
 breakpoints 12q13 or 12q14, 36:131  
 chromosome changes in, 32:11  
 t(1;12) and (3;12) in, 31:237; 32:11  
 t(7;21) in, 30:17; 32:11  
 +7 in angiomyolipoma, 34:219  
 12q13-14 not involved with fragile site at 12q13.1, 31:35; 32:11  
 12q14 in translocations in, 31:237, 32:11
- Liposarcoma  
 lymphocytes of cases with t(12;16) do not express fragile site at 12q13.1, 31:35

- metastatic, myxoid with t(12;16;16), 34:119
- myxoid, 34:117, 119
- t(12;16) as only anomaly, 34:117
- Lung cancer and tumors
  - c-myc amplification in SCLC, 30:213
  - chromosome changes in cell lines from SCLC, 30:213
  - followed by ANLL in a patient with an extra chromosome, 35:263
  - i(8q) or i(9q) in, 33:11
  - 3p in SCLC lines, 30:213
- Lymphocytes
  - breakage in cases with sarcoma, 33:299
  - breakage in patients with lymphoma, 33:51
  - new fragile sites, 33:1
  - SCE in patients with oral leukoplakia, 36:177
- Lymphoma
  - allotypes (Gm and Km) of immunoglobulin, 31:179
  - Burkitt cell line, 34:63
  - Burkitt lymphoma, 31:167; 32:67; 34:63
  - C-band studies in cases with, 31:175
  - centroblastic lymphoma with +5 and t(5;14), 36:173
  - chromosome breakage in patients with, 33:51
  - chromosome changes (gaps, breaks) after radiochemotherapy, 33:201
  - chromosome changes in BL, 32:67
  - chromosome changes induced by radiotherapy, 30:245
  - cutaneous T-cell, 30:65
  - cytogenetics of T-cell, 36:123
  - different clones in lymphoma, 36:173
  - karyotypic heterogeneity in BL, 34:63
  - presenting as bone tumor, 36:211
  - SCE and effects of drugs in cases with, 36:89
  - secondary blood disorder with Ph and 5q-, 30:253
  - t(4;11) in B-lymphoma, 36:159
  - T-cell, 30:63
  - unique t(7;15) in child with pre-B lymphoma, 36:211
  - +5 and t(5;14) in centroblastic, 36:173
- Malignant histiocytosis
  - PCC in, 35:37
- Medulloblastoma
  - cell line (D283 Med), 34:247
  - chromosome changes in, 30:91; 34:247
  - i(17q) in, 30:91
  - translocations in, 30:91; 34:247
  - #1 in, 30:91
  - 20q13 translocations, 30:91
- Melanoma
  - cell line, 32:117; 35:5, 253
  - chromosome changes in, 30:201; 35:5, 253
  - chromosome 15 in cell line, 32:117
  - dysplastic nevus syndrome, 35:73
  - effect of differentiating agents on NOR, 31:253
  - growth factor, 35:253
  - HSR in cell line, 32:117
  - karyotypes of cell lines, 32:117, 35:253
  - multiple chromosome changes in cell lines, 35:5
  - NOR activity in, 31:253
  - ocular melanoma, 32:129
  - trisomy 6p in ocular, 32:129
  - tumorigenicity of cell lines, 32:117
  - #1, 6, and 7 in melanoma, 30:201
  - 10q24-26 in melanocytic neoplasia, 30:313
  - 11p in melanoma, 35:5
- Meningioma(s)
  - chromosome changes in, 31:199; 32:11; 35:55
  - dicentrics, their origin, 35:55
  - secondary chromosome changes to -22, 33:275
  - 1, 14, 10 and 19 in, 31:199
  - 17, -Y in, 31:199
  - 22 in, 31:199; 32:11
  - 22q- in, 32:11
- Merkel cell carcinoma
  - chromosome changes in, 30:152
  - cytogenetic studies in, 30:151
  - #1 involvement, 30:151
  - 7q-, +6, +11 in, 33:305
- Mesothelioma
  - chromosome changes in, 33:251
  - malignant pleural, 33:251
  - 7, 22, and 1p11-22 in, 33:251
- Methods; see also Techniques
  - cytogenetic studies in cells fixed with Carnoy's, 34:159
  - DNA in cells fixed with Carnoy's, 34:159
  - for preparation of rat intestine chromosomes, 36:191
  - improved PCC, 30:301
  - methods for marrow, lymph nodes, blood, fibroblasts and tumors, 32:59
  - methotrexate and marrow metaphases, 33:213
  - phorbol as a mitogen in tumors, 34:165
  - thymidine release synchronization technique, 33:213
- MIC Workshops
  - second, on ANLL, 30:1-15
  - third, on MDS and preleukemia, 32:1-10



**Mitogens**

in CLL, 34:295

PHA, PWM and EBV, 34:295

**Molecular studies**

*bcr* in acute leukemias, 32:217

*bcr* in MDS with Ph-like chromosome, 35:151

*bcr* in PH-negative CML, 33:119; 35:223

*bcr* in variant Ph translocations, 35:179

*bcr* studies in Ph + CML, 35:179

biotinylated probe, 33:245

c-Ha-ras-1 homozygosity in adrenal adenoma, 30:127

c-myc in 6q - cell line, 33:83

c-myc and c-mos in sarcoma, 34:111

c-myc in colon adenocarcinoma, 33:245

chromosomal localization of c-myc, 33:245

CpG demethylation in CML, 34:251

Hu-ets-1 in congenital leukemia, 30:233

in a glioblastoma cell line with -13, -13, 33:127

in a poorly differentiated sarcoma, 34:111

in cells fixed with Carnoy's, 34:111

in CMMoL (c-K-ras-2), 35:61

Ki-ras-2 in ALL cell line, 30:239

*myc* amplification in SCLC cell lines, 30:213

myeloperoxidase gene and t(15;17) in APL, 30:103

N-myc in neuroblastoma cell lines, 30:225

N-myc in retinoblastoma, 30:119; 33:25

N-myc in Wilms' tumor, 30:187

restriction endonuclease (HpaII and MspI) studies in CML, 34:251

18q and #17 and integration site of hepatitis B DNA, 30:269

**Monosomy**

in endometrial cancer, 33:67

in MDS, 33:39

in secondary leukemia, 36:165

-5 in M7, 33:111

-5, -7 in radiotherapy-related leukemia, 31:227

-5, -7 in transformed MPD, 32:157

-5, -7, -17 in MDS, 32:1

-6, -9 in prostatic leiomyosarcoma, 30:339

-7 in ANLL, 30:4; 36:165

-7 in MDS, 31:148, 32:157; 33:39

-7 in radiotherapy-related leukemia, 31:227

-7 in secondary leukemia after treatment of HD, 36:165

-8 in renal cancer, 30:59

-9 in bladder tumor, 30:35

-14, -15, -18, -22 in leiomyosarcoma, 30:285

-17 in meningioma, 31:199

-21 in ANLL, 32:105

-22 in meningioma, 31:199

-22 in mesothelioma, 33:251

**Mouse**

chromosome changes in cell line (uroepithelial), 36:77

cytogenetic analysis of leukemia, 35:91

marker chromosome stability, 36:77

myelomonocytic leukemia in, 35:91

transformed uroepithelial cells, 36:77

**Multiple endocrine neoplasia (MEN)**

chromosome studies in, 35:273

fragile sties in, 35:273

type 2A, 35:273

**Multiple myeloma**

myelodysplasia in, 30:133

Robertsonian in patient dic(14;14), 30:133

**Mycosis fungoides**

chromosome changes, 30:65

**Myelodysplasia and myelodysplastic syndromes (MDS)**

acquired Robertsonian dic(14;14) in, 30:133

*bcr*-negative in MDS with Ph-like chromosome, 35:151

c-K-ras-2 in CMMoL, 35:61

chromosome changes in, 30:83, 133; 32:1, 64

chromosome study in 85 cases, 33:39

constitutional chromosome changes and, 35:243

del(8)(q22) in RAEB-t, 30:319

dic(16;22) in t-MDS, 35:143

distinct clones in, 35:213

Down syndrome and, 35:243

i(9p) in secondary MDS after multiple myeloma, 36:217

in MPD in acute transformation, 32:157

isodicentric X in, 30:45

MDS changing to MPD, 30:253

MDS following treated multiple myeloma, 30:133

monosomy 17p and trisomy 1q in, 35:21

Ph-like chromosome in, 35:151

secondary MDS, 30:133

secondary MDS and chromosome changes, 31:147

t(1;3)(p36;q21) in, 33:194

t(1;7)(p11;p11) in, 30:83; 32:7

t(1;17) in, 35:21

t(2;7) evolving to M4, 35:199

t(3;4) with megakaryoblastic proliferation in, 34:5

t(3;4;9;11;22) in CML, 30:164



- t(5;12) in CMMoL, 35:61
- t(11;21) in, 34:33
- t(Y;1)(q12;q21) in, 34:285
- Third Workshop on, 32:1
- trisomy 1q and monosomy 17p in, 35:21
- 5q- and Ph in MDS after treatment of gastric lymphoma, 30:253
- 6p rearrangements in, 31:147
- 6p+ and 9q- clones in, 35:213
- +8 in, 32:64
- +11 in CMMoL, 30:109, 159; 34:41
- +11 in MDS, 30:159; 35:205
- 11p15 in childhood MDS, 34:41
- Myelofibrosis
  - Idiopathic in transformation, 30:139
  - t(1;7) in, 36:45
  - 4;12 and 5;12 in, 30:139
  - 7q- in, 30:139
- Myelofibrosis with myeloid metaplasia (MMM)
  - cytogenetic changes in, 32:157
- Myeloma
  - chromosomes 1, 12, and 14 in, 35:27
  - double i(9p) in secondary MDS following, 36:217
  - i(17q) in plasma cell leukemia, 35:27
  - malignant and chromosome changes, 35:27
  - plasma cell leukemia, 35:27
  - survival and chromosomes, 35:27
- Myeloperoxidase
  - gene translocated in t(15;17) in APL, 30:103
- Myeloproliferative disorders (MPD)
  - acute and radiotherapy-related, 31:229
  - chromosomes in acute transformation of, 32:157
  - cytogenetics of chronic MPD, 32:157
  - following MDS and treatment of lymphoma, 30:253
  - idiopathic myelofibrosis with 4;12 and 5;12 and 7q-, 30:139
  - myeloid metaplasia, 32:157
  - polycythemia vera, 32:157
  - without a Ph, 32:157
  - 3p- in, 32:64
  - 5q- and Ph in secondary MPD, 30:253
- Myxoid tumors
  - chondrosarcoma with t(9;22;15), 30:145
  - histiocytomas, chromosome changes in, 30:23
- Nasopharyngeal cancer
  - fragile site 1q44 and, 35:135
  - t(1;3) in, 35:135
- Neuroblastoma
  - cell lines, 30:225
  - constitutional 1p- in patient with, 34:235
  - cytogenetics of cell lines, 30:225
  - expression in leukemia, 35:109
  - in ALL, AML and CML, 35:109
  - N-myc in, 30:225
  - stages in neoplastic evolution in hamster cells, 35:119
  - temporal variations expressing in leukemia, 35:109
  - 1p fragile site in lymphocytes of cases with, 36:13
  - 1p- in cell lines, 30:225; 34:235
  - 1p- in patient and tumor, 34:235
  - 1p13.1 fragile site in, 31:83
- Neuroectodermal tumors
  - cytogenetic abnormalities, 32:247
  - inv(7), 3p-, and t(3;10) in, 32:247
  - primitive, 32:247
- Neuroendocrine tumors
  - chromosome changes in, 30:151
  - Merkel cell carcinoma, 30:151
  - #1 involvement, 30:151
- Neuroepithelioma
  - peripheral (primary), 33:291
  - soft tissue, 33:291
  - t(11;22)(q24;q12) in, 33:291
- Nucleolar Organizer Region (NOR)
  - activity in melanoma cells, 31:253
  - effect of differentiating agents, 31:253
- Oncogene(s)
  - biotinylated c-myc probe, 33:245
  - c-Ha-ras-1 in adrenal adenoma, 30:127
  - c-K-ras-2 and t(5;12) in MDS, 35:61
  - c-K-ras-2 overexpression in MDS, 35:61
  - c-myb in T-cell leukemia cell line with 6q-, 33:83
  - c-myc and c-mos in sarcoma, 34:111
  - c-myc in colon adenocarcinoma, 33:245
  - chromosomal localization, 33:245
  - chromosome locations, 31:145
  - Hu-ets-1 in congenital leukemia, 30:233
  - increased copy in retinoblastoma, 30:119
  - Ki-ras-2 in ALL cell line, 30:239
  - N-myc in neuroblastoma cell lines, 30:225
  - N-myc in retinoblastoma, 30:119; 33:25
  - N-myc in Wilms' tumor, 30:187
  - papillomavirus integration sites and, 33:93
  - protooncogenes in AML and preleukemia, 32:133
- Orchidoblastoma
  - of testes, 36:7
  - without i(12p), 36:7

- Osteosarcoma  
 chromosome changes in, 32:149
- Ovarian tumors  
 chromosome changes in, 35:83  
 ependymoma, 35:83  
 teratoma, 35:83
- Parotid gland  
 cystadenolymphoma with t(11;19),  
 35:129  
 Warthin's tumor, 35:129
- Philadelphia chromosome (Ph)  
 bcr and Ph-like chromosome in MDS,  
 35:151  
 bcr in acute leukemias, 32:217  
 bcr in Ph - CML, 33:119  
 five Phs in CML, 34:257  
 in childhood ALL, 32:183  
 t(3;9;22), 35:279  
 t(9;11;22), masked, 34:53
- Philadelphia translocation and  
 chromosome  
 in secondary blood disorder with 5q -,  
 30:253  
 "masked" due to t(X;22), 30:333  
 Ph + ALL, 32:64  
 variant and fragile sites, 31:105  
 variant translocations, 32:75  
 t(1;9;22), 32:76  
 t(2;9;22), 32:76  
 t(2;13;22), 32:76  
 t(3;9;22), 31:106  
 t(4;9;22), 32:76  
 t(4;18;13;9;22) in CML, 30:163  
 t(5;9;22), 31:107; 32:76  
 t(6;9;22), 31:107  
 t(7;9;11;22), 32:76  
 t(7;9;22), 31:108  
 t(9;10;22), 31:108, 109  
 t(9;11;22), 31:109; 32:76  
 t(9;14;22), 32:76  
 t(9;15;22), 32:76  
 t(9;16;22), 32:76  
 t(9;17;22), 32:76  
 t(21;22;22), 32:76
- Phorbol  
 as a mitogen, 34:165  
 use as mitogen in tumors, 34:165
- Plasma cell leukemia; see also Myeloma  
 chromosome changes in, 35:27  
 i(17q) in, 35:27
- Polycythemia vera (PV)  
 chromosome changes in, 32:157  
 t(1;3)(p36;q21) in, 33:194  
 transformation and t(1;3)(p36;q21),  
 33:193
- Preleukemia; also see Myelodysplasia  
 acute transformation of MPD, 32:157  
 chromosome changes in, 31:148; 32:1  
 chromosome instability in, 30:191  
 hypothesis in development, 32:133  
 isodicentric X in, 30:45  
 pre-ATL, 30:191  
 protooncogenes in, 32:133  
 radiotherapy-related, 31:227
- Premature chromosome condensation  
 (PCC)  
 improved technique, 30:301  
 in ALL and malignant histiocytosis,  
 35:37
- Probes  
 biotinylated, 33:245  
 c-myc, 33:245  
 chromosomal localization, 33:245  
 in colon adenocarcinoma, 33:245  
 in glioblastoma cell line, 33:127
- Prolymphocytic leukemia (PLL)  
 chromosome changes in, 30:65
- Prophasing; see also Premature  
 chromosome condensation  
 improved technique, 30:301  
 in ALL and malignant histiocytosis,  
 35:37
- Prostate  
 adenocarcinoma cell line (PC-82), 34:91  
 chromosome changes, 30:339; 35:103  
 del(7q) and del(10q) in adenocarcinoma,  
 35:103  
 leiomyosarcoma of, 30:339
- Radiation  
 persistent chromosome damage by  
 localized radiotherapy, 30:245
- Rat  
 metaphases of rat intestine, 36:191  
 method of chromosome preparation,  
 36:191
- Rectal or Colorectal tumors; see large  
 bowel tumors
- Refractory anemia (RA)  
 chromosome changes in, 31:148; 36:45  
 t(1;7) in, 30:86, 88; 36:45  
 t(11;21) in, 34:33  
 Third Workshop (MIC), 32:1  
 6p rearrangements in, 31:148  
 11p15 in childhood, 34:41
- Refractory anemia with excess of blasts  
 (RAEB); see also Myelodysplasia  
 bcr in case with Ph-like chromosome,  
 35:151  
 chromosome changes in, 31:148, 167;  
 32:1; 33:39  
 dic(16;22) in, 35:143  
 distinct clones in, 35:213  
 in transformation of MPD, 32:160, 161,  
 162

- isodicentric X in, 30:45
- sex chromosome anomalies and, 35:243
- t(1;3)(p36;q21) in, 33:194
- t(1;16) in, 31:167
- t(3;4) with megakaryoblastic proliferation, 34:5
- t(3;11) in, 31:167
- t(11;21) in, 34:33
- t(Y;1)(q12;q21) in, 34:285
- Third MIC Workshop, 32:1
- 1q+ in cases with, 31:165
- 6p rearrangements in, 31:148
- 6p+ and 9q- clones in, 35:213
- Refractory anemia with excess of blasts in transformation (RAEB-t)
  - case changing to AML (M2) with an abnormal 16 and eosinophilia, 31:217
  - chromosome changes in, 33:39
  - del(8)(q22) in, 30:319
  - DMS in, 34:47
  - HSR breakdown into DMS, 34:47
  - t(11;21) in, 34:33
  - Third MIC Workshop, 32:1
  - transforming to M4, 30:319
  - 6p rearrangements in, 31:148
  - +11 in, 35:205
  - 11p15 in childhood, 34:41
- Refractory anemia with ring sideroblasts (RARS)
  - chromosome changes in, 33:39
  - t(1;7) in, 30:84
  - t(11;21) in, 34:33
  - Third Workshop (MIC), 32:1
  - 5q- in, 32:65
- Renal tumors
  - binucleated cells in, 31:211
  - carcinoma with 3p- in von Hippel-Lindau, 33:59
  - chromosome changes in cell line, 33:133
  - chromosome changes in nonfamilial, 34:135; 35:41
  - chromosomes 1, 3, 7, 8, and 14 in, 30:53; 34:135
  - chromosomes 3 and 5 in cancer, 35:41
  - cytogenetics of adenocarcinoma, 30:53; 34:135
  - double-loss mechanism, 36:197
  - fragile site at 3p14, 31:75
  - fragile sites in tumors with t(3;8), 31:69
  - genomic defects in, 34:135
  - hereditary RCC, 36:197
  - in von Hippel-Lindau syndrome, 33:59
  - intratumor chromosome heterogeneity, 32:35
  - karyotypes in cancer, 35:41
  - recessive genes in RCC, 36:197
  - renal cancer cell line, 33:133
  - Wilms' tumor with t(11;11), 33:145
  - with hypodiploidy (34 chromosomes), 31:211
  - Xp11 in, 30:53
  - 1q21 in, 30:53
  - 3p in, 33:59, 133; 34:133, 135
  - 3p in RCC, 36:197
  - 3p11-21 in, 30:53; 31:69, 75; 32:35
  - +7 or +7, +7 in renal cancer, 34:135
  - 14q22 in, 30:53
- Restriction Endonuclease
  - HpaII and MspI, 34:251
  - studies in CML, 34:251
- Retinoblastoma
  - amplified N-myc in cell line, 33:25
  - bilateral, with 13q- mosaicism, 32:169
  - chromosome abnormality and N-myc, 30:119
  - chromosome changes in, 31:167
  - germinal mutation in, 32:169
  - N-myc in, 30:119; 33:25
  - SCE in patient with mosaic 13q-, 32:177
  - t(1;19) in, 31:167
  - 1q+ in, 31:165
  - 13q- mosaicism, 32:169
- Rhabdomyosarcoma
  - congenital with t(2;8), 30:343
  - in Roberts syndrome, 31:285
  - t(2;8) in, 30:343
- Ring chromosomes
  - in CLL, r(1), 33:156
  - in histiocytoma, 30:23
  - in meningioma, 33:275
  - in mesothelioma, 33:251
  - in myelodysplasia, 33:39
  - in T-cell malignancies, 30:65
  - r(1) in leiomyoma of uterus, 36:183
  - r(6) in APL, 34:273
- Roberts syndrome
  - rhabdomyosarcoma in, 31:285
- Robertsonian translocations
  - in cancer, 35:79
  - rarity in cancer, 35:79
- Salivary gland tumor(s)
  - cystadenolymphoma with t(11;19), 35:129
  - benign, chromosomes in, 32:11
  - effects of tissue culture techniques on cytogenetics, 33:229
  - pleomorphic with t(3;8), 35:281
  - t(3;8) in, 33:229; 35:281
  - t(11;19) in parotid tumor, 35:129
  - translocations in, 32:11
  - Warthin's tumor with t(11;19), 35:129
  - 8p changes in, 31:301
  - 8q12, 12q13-15, 3p21 in, 33:229



## Sarcoma

- c-myc and c-mos in a poorly differentiated sarcoma, 34:111
- chromosome breakage in patients with musculoskeletal, 33:299
- endometrial (stromal) with t(10;19), 36:1
- Ewing's sarcoma, 31:167; 32:229, 239
- fibrosarcoma with t(X;18), 30:323
- granulocytic of small intestine, 35:231
- ins(10;19) in endometrial sarcoma, 36:1
- leiomyosarcoma of extremities, 34:209
- leiomyosarcoma of prostate, 30:339
- leiomyosarcoma of retroperitoneum, 35:47
- leiomyosarcoma of small bowel, 30:285
- liposarcoma with t(12;16), 34:117
- metastatic liposarcoma with t(12;16;16), 34:119
- monosomy 9, 18, and 22 in leiomyosarcoma, 35:47
- M4 with inv(16) and eosinophilia following sarcoma, 35:231
- osteosarcoma, 32:149
- rhabdomyosarcoma (congenital), 30:343; 31:285
- synovial, 30:183
- 1p13 and 11p13 in leiomyosarcoma, 35:47
- 46,XX,-8,+mar in a sarcoma, 34:111
- Secondary leukemias; see Treatment-related leukemias
- after treatment of HD, 36:165
- antineoplastic agents and, 33:201
- case with t(8;21)?, 31:271
- in lymphocytes of patients with oral leukoplakia, 36:177
- in MPD, 32:157
- long-term cytogenetic effects of therapy, 33:201
- multiple clones in squamous cell cancer, 36:149
- Sézary syndrome
  - chromosome changes in, 30:65
- Sister chromatid exchange (SCE)
  - betel chewing and SCE, 32:211
  - effect of oral contraceptives, 32:211
  - effects of drug regimens in lymphoma, 36:89
  - frequency in lymphocytes of lymphoma cases, 36:89
  - in marrow, 31:157
  - in patient with retinoblastoma and 13q- mosaicism, 32:177
  - in pregnant women, 32:211
  - levels in uremia, 36:55
  - SCE after cytostatic agents, 31:157; 36:89

## Skin

- chromosome changes in squamous cell carcinoma, 36:149
- cancer in xeroderma pigmentosum patient, 33:29
- multiple clones in squamous cell cancer, 36:149
- squamous cell cancer, 33:29; 36:149
- Squamous cell carcinoma
  - chromosome changes in, 33:29
  - chromosome 14 in, 33:29
  - chromosomes in, 36:149
  - cytogenetics of, 32:93
  - in situ, 36:149
  - inv(4) in, 36:233
  - multiple unrelated clones, 36:149
  - of hypopharynx with inv(4), 36:233
  - of skin, 33:29; 36:149
  - of skin in xeroderma pigmentosum, 33:29
  - of tongue, 32:93
  - unrelated clonal chromosome abnormalities, 32:93
- Synovial sarcoma
  - t(X;18) and ins(15;11) in, 30:183
  - t(X;18) in, 33:311
- T-cell malignancies
  - adult T-cell leukemia line, 34:77
  - ALL (T-cell) with t(1;18), 30:165
  - ALL (T-cell) with t(9;11), 31:263
  - c-myc in T-cell cell line with 6q-, 33:83
  - chromosomes in pre-ATL, 30:191
  - CLL, 30:65
  - cutaneous lymphoma, 30:65
  - cytogenetics of, 30:63
  - cytogenetics of T-cell lymphoma, 36:123
  - immunoblastic sarcoma, 30:65
  - mycosis fungoides, 30:65
  - PLL, 30:65
  - Sézary syndrome, 30:65
  - T-cell line with 6q-, 33:83
- Technique(s)
  - for culturing and harvesting of marrow, lymph nodes, etc., 32:59
  - for PCC, 30:301
  - for solid tumors, 32:59
  - method for rat intestine chromosomes, 36:191
  - methotrexate for bone marrow, 33:213
  - molecular in cells fixed with Carnoy's 34:159
  - phorbol as a mitogen in tumors, 34:165
  - robotic harvesting, 32:59
  - thymidine release synchronization, 33:213



- Telomeric association  
  in histiocytoma, 30:23
- Teratoma  
  after testicular germ cell tumor, 32:51  
  chromosome changes in, 32:51  
  mature with balanced karyotype, 32:51  
  of ovary with +3, 35:83
- Testicular tumors  
  a new subgroup?, 35:171  
  combined tumor, 35:161  
  germ cell tumor, 32:53; 35:159, 171  
  i(12p) in, 32:53; 35:159  
  i(12p)-negative tumor, 35:171  
  karyotype in, 32:53; 35:159, 171  
  nonseminoma, 32:51; 35:159  
  nonseminomatous part, 35:161  
  orchidoblastoma without i(12p), 36:7  
  residual teratoma with simpler  
    karyotype, 32:53  
  seminomatous part, 35:160
- Tetraploidy  
  in acute mixed-lineage leukemia, 33:185  
  – Y and tetraploidy, 33:185
- Thrombocythemia, essential (ET)  
  cytogenetic changes in, 32:157
- Thrombopoiesis and thrombocytosis  
  inv(3)(q21q26), 30:3  
  t(3;6) with basophilia in AML, 30:261
- Tongue  
  complex chromosome changes in a  
    cancer, 32:93  
  squamous cell cancer in, 32:93
- Translocations  
  dic(14;14), Robertsonian, 30:133  
  dic(16;22) in ANLL and MDS, 35:143  
  five Phs and (1;17) in CML, 34:257  
  in a squamous cell carcinoma, 32:93  
  in acute transformation of MPD, 32:157  
  in adult T-cell leukemia cells, 34:77  
  in an ependymoma, 36:25  
  in ANLL, 34:11  
  in Burkitt cell line, 34:63  
  in childhood ALL, 32:183  
  in colorectal tumors, 32:43  
  in dysplastic nevus syndrome, 35:73  
  in endometrial cancer, 33:67  
  in Ewing's sarcoma, 32:229  
  in leiomyosarcoma, 34:209; 35:47  
  in MDS, 33:39  
  in meningiomas, 33:275  
  in mesothelioma, 33:251  
  in myeloma and plasma cell leukemia,  
    35:27  
  in Ph-negative CML, 35:223  
  in prostate cancer, 35:103  
  in prostatic cancer line, 34:91  
  in salivary gland tumors, 33:229  
  in squamous cell cancer of skin, 36:149  
  in testicular tumors, 32:51  
  in Wilm's tumor, 34:223  
  Ph translocations (variant) 35:179  
  Robertsonian in cancer, 35:79  
  variant Ph translocations, 32:76; 35:179  
  variant translocations in Ewing's  
    sarcoma, 32:229  
  (X;1) in renal cancer, 30:59  
  (X;3) in renal cancer, 33:59  
  (X;4) in a leiomyosarcoma, 34:209  
  (X;12) in leiomyoma of uterus, 32:11  
  (X;18) in fibrosarcoma, 30:323  
  (X;18) in synovial sarcoma, 30:183;  
    33:311  
  (X;19) in oligoblastic granulocytic  
    leukemia, 35:237  
  (X;22) and "masked" Ph, 30:333  
  (Y;1), (8;14) in Burkitt lymphoma,  
    31:167  
  (1;2) in ATL, 30:193  
  (1;3) in MDS, 32:6  
  (1;3) in Merkel cell cancer, 30:152  
  (1;3) in nasopharyngeal cancer, 35:135  
  (1;3) in renal cancer, 30:59  
  (1;3) in transformed PV, 33:193  
  (1;3)(p36;q21) in various disorders,  
    33:194  
  (1;6;11) in CLL, 30:65  
  (1;7) in MDS, 36:7  
  (1;7) in meningioma, 31:203  
  (1;7) in myelofibrosis and RA, 36:45  
  (1;10) in histiocytoma, 30:27  
  (1;11) in neuroblastoma cell line, 30:226  
  (1;12) in lipoma, 31:237  
  (1;14) in ATL, 30:192  
  (1;14) in renal cancer, 30:59  
  (1;16) in AML, 31:167  
  (1;16) in Ewing's sarcoma, 32:239  
  (1;17) in MDS, 35:21  
  (1;17) in melanoma, 30:206  
  (1;18) in T-cell ALL, 30:165  
  (1;19) and (12;17) in pre-B-cell ALL,  
    31:275  
  (1;19) in retinoblastoma, 31:167  
  (1;19) in T-cell ALL, 30:165  
  (1;19), (9;14), (5;9) in ALL, 33:99  
  (1;22) in M7 (congenital), 34:277  
  (2;7) in ANLL evolving from MDS,  
    35:199  
  (2;8) in congenital rhabdomyosarcoma,  
    30:343  
  (2;11) in MDS, 32:6  
  (2;11;19) in prostatic leiomyosarcoma,  
    30:339  
  (2;14) in CLL, 30:65  
  (2;14) in leiomyoma of uterus, 32:11

## Translocations—cont'd.

- (2;18) in ATL, 30:192
- (3;4) in MDS, 34:5
- (3;6) in AML with basophilia and abnormal thrombopoiesis, 30:261
- (3;6) in MDS, 31:148
- (3;7), (4;9) in Ph-negative CML, 31:241
- (3;8) in mixed tumor of salivary gland, 32:11; 33:229
- (3;8) in renal cancer, 30:59; 31:69
- (3;9) in MDS, 31:148
- (3;9;22) Ph translocation in CML, 35:279
- (3;9;22), Ph variant, 31:106
- (3;11) in AML (M2), 31:219
- (3;11) in mycosis fungoides, 30:65
- (3;11) in RAEB, 31:167
- (3;12) in lipoma, 31:237; 32:11
- (3;12) in renal cancer, 30:59
- (3;14) in immunoblastic sarcoma, 30:65
- (3;17) in leiomyoma of uterus, 32:19
- (3;21) in CML, 35:133
- (4;8) in meningioma, 31:203
- (4;8) in renal cancer, 30:59
- (4;11) and (7;11) in childhood MDS, 34:41
- (4;11) in AMoL (M5) in infant, 35:167
- (4;11) in Burkitt-like blasts, 34:89
- (4;11) in lymphoma, 36:159
- (4;12) and (5;12) in myelofibrosis, 30:139
- (4;18;13;9;22) Ph in CML, 30:163
- (5;6;10) in melanoma, 30:313
- (5;9;22), Ph variant, 31:107
- (5;12) in CMMoL, 35:61
- (5;14)(q11;q32) in controblastic lymphoma, 36:173
- (5;20) in medulloblastoma, 30:93
- (5;21) in CMMoL, 31:247
- (6;7) in melanoma, 30:206
- (6;9) in MDS, 32:6
- (6;9) in M2 and M4, 30:3
- (6;9;22), Ph variant, 31:107
- (6;14) in CLL, 30:65
- (6;16) in MDS, 31:148
- (6;17) in myeloid metaplasia, 32:65
- (7;9) in melanoma, 30:206
- (7;9;22), Ph variant, 31:108
- (7;12) in a hypereosinophilic syndrome, 32:109
- (7;12) in CLL, 30:65
- (7;14) in ATL, 30:192
- (7;15) in childhood lymphoma, 36:211
- (7;18) in melanoma, 30:206
- (7;21) in lipoma, 30:17; 32:11
- (7;21)(p14;q11) in Ph + CML, 33:225
- (7;22) in lipoma, 32:11
- (8;9) in histiocytoma, 30:27
- (8;9) in Ph-negative CML, 35:51
- (8;12) in melanoma, 30:206
- (8;14) and 1p- in long survival ALL, 32:143
- (8;14) in Burkitt lymphoma, 32:67
- (8;16) in AMoL, 34:265; 36:109
- (8;16) in M4, 36:137
- (8;16) in M5b, 30:3
- (8;18;21) in ANLL (M2), 36:231
- (8;21) and its variants, 33:163
- (8;21) in ANLL, 33:161
- (8;21) in granulocytic hyperplasia, 31:193
- (8;21) in M2, 30:3; 32:101
- (8;21), (15;17), (9;11), (1;16) in ANLL, 32:101
- (8;22) in Burkitt lymphoma, 32:67
- (9;9) in B-cell ALL, 30:295
- (9;10;22), Ph variant, 31:108, 109
- (9;11) in T-cell ALL, 31:263
- (9;11;13) in ANLL, 30:171
- (9;11;18) in ANLL, 30:171
- (9;11;22), masked Ph, 34:53
- (9;11;22), Ph variant, 31:109
- (9;12) in mixed tumor of salivary gland, 32:11
- (9;13)(p22;q12) in ALL, 33:149
- (9;13), (11;18) in laryngeal cancer, 30:177
- (9;14) in meningioma, 31:203
- (9;22) in M1 (M2), 30:3
- (9;22), Ph- in secondary blood disorder, 30:253
- (9;22;15) in chondrosarcoma, 30:145
- (10;11;15) in ependymoma, 30:289
- (10;12) in histiocytoma, 30:27
- (10;18) in renal tumor, 32:37
- (10;19) and (11;14) in B-CLL, 34:295
- (10;22) in T-cell lymphoma (CTCL), 30:65
- (11;11) in ANLL, 36:225
- (11;11)(p13;p15) in Wilms' tumor, 33:145
- (11;14) in B-CLL, 31:25
- (11;14), (9;20) in CLL, 33:156
- (11;19) in congenital leukemia, 30:233
- (11;19) in MDS, 31:148
- (11;19) in parotid gland tumor, 35:129
- (11;21) in MDS, 32:6; 34:33
- (11;21) in Ph + CML, 31:187
- (11;22) in peripheral neuroepithelioma, 33:291
- (11;22), (1;16) in Ewing's sarcoma, 31:167
- (12;13) in AML (M2), 31:219
- (12;14) in leiomyoma of uterus, 32:11, 14, 27; 36:183
- (12;14) in renal tumor, 32:37
- (12;16) as sole change in liposarcoma, 34:117

- (12;16;16) in metastatic myxoid liposarcoma, 34:119
- (12;19) in ANLL with atypical erythropoiesis, 34:19
- (12;22) in leiomyoma of uterus, 32:19
- (14;15) in ATL, 30:192
- (14;18) in ATL, 30:192
- (14;20) in renal tumor, 32:37
- (15;17) and (9;14) in APL, 36:103
- (15;17) in meningioma, 31:203
- (15;17) in M3, 30:3, 103, 329; 32:101
- (15;19) in ATL, 30:192
- (16;21) in ANLL with abnormal eosinophils, 36:221
- (17;17) in T-cell lymphoma (MF), 30:65
- (17;22) in meningioma, 31:203
- Treatment-related leukemias and MDS
  - after treatment of HD, 36:165
  - ALL following radiotherapy, 31:227
  - ANLL following radiotherapy, 31:227
  - case with t(8;21)?, 31:271
  - chromosome changes (gaps, breaks) after radiochemotherapy, 33:201
  - clinical and cytologic characteristics, 31:227
  - cytogenetic findings in, 31:227; 32:1; 33:201
  - long-term cytogenetic effects, 33:201
  - Ph+ CML following radiotherapy, 31:227
  - radiochemotherapy effects, 33:201
  - radiotherapy-related, 31:227; 33:201
  - translocations in ALL, 33:99
  - treatment-related MDS; 32:1
  - 5q- and -7 in ANLL, 31:227
  - 7 and 12p- in ALL, 31:227
- Trisomy
  - in endometrial cancer, 33:67
  - in meningioma, 33:275
  - in myelodysplasias, 33:39
  - XXX and ANLL, 35:1
  - +3 in ovarian teratoma, 35:83
  - +3, +8, +20 in a testicular tumor, 32:53
  - +4 in M1 and M2, 34:29
  - +4 in M2, 34:281
  - +4 in M4 (M2), 30:3; 33:19; 34:25; 36:155
  - +5 in ALL, 36:31
  - +5 in centroblastic lymphoma, 36:173
  - +6, +11 in Merkel cell carcinoma, 33:305
  - 7 in mesothelioma, 33:251
  - +7 and +7, +7 in renal tumors, 34:135
  - +7 in angiomyolipoma, 34:219
  - +7 in bladder tumor, 30:35
  - +7 in renal cancer, 30:57; 32:37
  - +8 in ANLL, 30:4; 32:105
  - +8 in colonic adenoma, 32:11
  - +8 in Ewing's sarcoma, 32:239
  - +8 in MDS, 32:64, 157; 33:39
  - +8 in transformed MPD, 32:157
  - +8, +19 in AMoL (M6) in infant, 35:167
  - +8 and +21 in MDS, 32:7
  - +9 and +18, +19 in CLL, 33:155
  - +11 in ANLL and MDS, 35:205
  - +11 in CMMoL, 30:109
  - +11 in myelodysplasia, 30:159
  - +12 in CLL, 33:155
  - +17 in renal tumors, 34:135; 35:42
  - +22 in ANLL, 30:4; 32:104
- Tumors
  - benign, chromosomes in, 32:11
  - bladder, 30:35
  - brain, 30:91, 31:199
  - chondrosarcoma, 30:145
  - ependymoma, 30:289
  - favorable prognosis with low chromosome counts, 34:121
  - fibrosarcoma, 30:323
  - genetic instability in, 34:125
  - histiocytoma, 30:23
  - laryngeal, 30:177
  - leiomyosarcoma, 30:285, 339
  - lipoma with t(7;21), 30:17; 32:11
  - medulloblastoma, 30:91
  - melanoma, 30:201
  - Merkel cell cancer, 30:151
  - metastatic and benign: genetic stability, 34:125
  - methods for cytogenetic analysis, 32:59
  - neuroectodermal, cytogenetics of, 32:247
  - of ovary, 35:83
  - of salivary glands, 33:229
  - phorbol as mitogen in tumors, 34:165
  - renal, 30:53; 31:69, 75, 211; 32:35
  - rhabdomyosarcoma, 30:343
  - sarcoma, 30:183, 285
  - t(7;21) in lipoma, 30:17, 32:11
  - testicular, 32:51
  - 1q+ in, 31:165
- Uremia
  - chromosome changes in, 36:55
  - SCE in, 36:55
- Uterine tumors
  - del(7q) in myoma, 34:207
  - endometrial cancer, chromosome changes, 33:67
  - endometrial sarcoma with ins(10;19), 36:1
  - ins(14;6)(q23;p23p25) in leiomyoma, 34:201
  - leiomyoma, chromosomes, 32:11, 13, 19; 34:201; 36:183
  - myoma with t(12;14), 36:183
  - r(1) in leiomyoma, 36:183



## Uterine tumors—cont'd.

- #1 changes in leiomyoma, 36:183
- 3, 12, 14, 17 and 22 in leiomyoma, 32:19
- 12 and 14 in leiomyoma, 32:27; 36:183
- 12q in leiomyoma, 32:33; 36:183
- 14q in leiomyoma, 32:25; 34:201; 36:183
- 14q23 in leiomyoma, 34:201

## Virus(es)

- in cervical cancer cell line, 33:93
- localization of papillomavirus integration sites, 33:93

## von Hippel-Lindau syndrome

- fragile sites in, 31:41
- high-resolution banding, 31:41
- renal cancer with 3p- in, 33:59

## Warthin's tumor

- of parotid gland, 35:129
- t(11;19) in, 35:129

## Wiedemann-Beckwith syndrome

- adrenal adenoma in, 30:127
- c-Ha-ras-1 in adrenal adenoma, 30:127
- 11p and adrenal adenoma, 30:127

## Wilms' tumor

- chromosome changes in, 34:223
- insulin-like growth factor II in, 33:145
- N-myc amplification, 30:187
- t(11;11)(p13;p15) in, 33:145

## X chromosome

- abnormalities and leukemia, 35:243
- constitutional changes and leukemia, 35:243
- del(X) in melanoma, 30:206

in leiomyoma of uterus, 32:11

- inactive X involved in t(X;19), 35:237
  - isodicentric X in ANLL, 30:43
  - isodicentric X in MDS, 30:43
  - r(X) in T-cell lymphoma (CLL), 30:65
  - t(X;3) in renal tumor, 33:59
  - t(X;4) in leiomyosarcoma, 34:209
  - t(X;19) in oligoblastic granulocytic leukemia, 35:237
  - t(X;22) and "masked" Ph, 30:333
  - X/XX/XXX mosaicism in cases of von Hippel-Lindau syndrome, 31:41
  - XXX constitution and ANLL, 35:1, 243
  - +X, +X in testicular tumor, 32:53
  - X in ependymoma, 30:289
  - X in renal tumors, 32:37
  - X in t(8;21), 32:104
  - Xp11 (t) in MDS, 32:7
  - Xp13 (t or dup) in MDS, 32:7
  - Xq13 in MDS and ANLL, 30:43
- Xeroderma pigmentosum
- chromosome 14 in skin cancer, 33:29
  - skin squamous cell cancer in, 33:29

## Y chromosome

- constitutional changes and leukemia, 35:243
- leukemia and XYY males, 30:337
- loss (-Y) in ANLL, 30:4; 33:161
- Y and tetraploidy in acute mixed leukemia, 33:185
- Y in bladder tumors, 30:37
- Y in MDS, 33:39
- Y in meningiomas, 31:199; 33:275
- Y in renal tumors, 34:135; 35:41

